



Global Cancer

Occurrence, Causes,
and Avenues to Prevention

*A conference to discuss today's challenges
and help design tomorrow's agenda*

PROGRAMME

7–10 JUNE 2016
Lyon, France

Programme at a glance

TUESDAY 7 JUNE 2016

16:00 – 20:00	Registration
18:00 – 19:30	Opening Reception

LEGEND

- ☐ All plenary sessions and panel debates will be held in **Amphithéâtre 3000, on level 0**
- ☒ Parallel sessions on “Epidemiology” will be held in **Amphithéâtre 3000, on level 0**
- ☒ Parallel sessions on “Mechanisms” will be held in the **Tête d’Or rooms, on level 1**
- ☒ Parallel sessions on “Prevention & Mortality Reduction” will be held in the **Gratte-Ciel rooms, on level 2**
- ☒ The poster area is **on level –2**
- ☒ Lunch and coffee breaks will be served **on level –2, including in the poster area**
- ☐ The conference dinner will be served **on level –2**



To find all the conference abstracts, go to the detailed programme page on the conference website:

www.iarc-conference2016.com/programme

To find your way through the Congress Centre, see the venue map at the back of the programme, on page 42.

WEDNESDAY 8 JUNE 2016

7:00 – 8:30	Registration
8:30 – 9:10	Opening Ceremony
9:10 – 9:40	Christopher P. Wild IARC: 50 years of cancer research for cancer prevention
9:40 – 10:00	HRH Princess Dina Mired Caring about cancer
10:00 – 10:30	Douglas Lowy The potential of cost-effective precision medicine in the low- and middle-income countries
10:30 – 11:00	Coffee break
11:00 – 11:30	Freddie Bray The global burden of cancer
11:30 – 12:15	Panel Debate 1 Cancer research investment should shift from late-stage treatment to early-stage detection Pro: Rengaswamy Sankaranarayanan Anti: Soo Khee Chee
12:15 – 14:00	Lunch break and Poster session
14:00 – 14:30	Michael Stratton Signatures of mutational processes in human cancer
14:40 – 15:40	Parallel Sessions (details on page 13) E M P
15:40 – 16:00	Coffee break
16:00 – 17:00	Parallel Sessions (details on page 14) E M P
17:10 – 17:40	Recipient of 2016 IARC Medal of Honour Elizabeth Blackburn The American Association for Cancer Research Lecture Telomeres, biology and cancer
17:40 – 18:10	David Hunter Cancer, NCDs and global health

Programme at a glance

THURSDAY 9 JUNE 2016

8:00 – 9:00	"50 for 50" parallel sessions For "50 for 50" fellows only		
9:00 – 9:30	Stephen Chanock Germline mutations		
9:30 – 10:00	Valerie Beral The impact of tobacco, alcohol and hormones on women's cancers		
10:00 – 10:30	Recipient of 2016 IARC Medal of Honour Lynette Denny Screening and early detection of cervical cancer in Africa		
10:30 – 11:00	Coffee break		
11:00 – 12:00	Parallel Sessions (details on page 21)		
	E	M	P
12:10 – 12:55	Panel Debate 2 E-cigarettes represent a barrier to effective tobacco control Pro: Armando Peruga Anti: Jean-François Etter		
12:55 – 14:30	Lunch break and Poster session		
14:30 – 15:30	Parallel Sessions (details on page 22)		
	E	M	P
15:30 – 16:00	Coffee break		
16:00 – 17:00	Parallel Sessions (details on page 23)		
	E	M	P
17:10 – 17:40	Michael Marmot Reducing inequalities in risk		
17:40 – 18:10	Graham Colditz Implementing strategies to prevent cancer		
18:30 – 19:00	Jazz Concert (in Amphithéâtre 3000)		
19:30	Conference Dinner		

FRIDAY 10 JUNE 2016

8:00 – 9:00	"50 for 50" parallel sessions For "50 for 50" fellows only		
9:00 – 9:30	Walter Willett The American Institute for Cancer Research and World Cancer Research Fund International Lecture Diet, weight control and energy balance in cancer		
9:30 – 10:00	George Davey Smith Causality and chance in the origins of cancer		
10:00 – 10:30	Flora van Leeuwen Risk factors for second cancers		
10:30 – 11:00	Coffee break		
11:00 – 12:00	Parallel Sessions (details on page 29)		
	E	M	P
12:10 – 12:55	Panel Debate 3 Screening for lung cancer should be implemented now Pro: John Field Anti: Harry J. de Koning		
12:55 – 14:00	Lunch break and Poster session		
14:00 – 15:00	PROFFERED PAPERS PLENARY SESSION 1. Ling Yang (China) 2. Ausrele Kesminiene (IARC) 3. Loic Le Marchand (USA) 4. Stephen Hecht (USA) 5. Rafaela Naves (Brazil) 6. Willie Yu (Singapore)		
15:00 – 15:30	Elio Riboli Consortia, big data and the future of population research		
15:30 – 16:00	Richard Peto Successes in understanding the causes of cancer		
16:00 – 16:30	Closing of Conference		



Welcome

Christopher P. Wild, Director, IARC

As Director of the International Agency for Research on Cancer (IARC), it is my great pleasure to welcome you to Lyon as we assemble from around the world to consider “Global cancer: occurrence, causes and avenues to prevention”.

The conference marks the 50th anniversary of the creation of IARC. The early events and many of the key contributions made by the Agency to cancer research are highlighted in our recent book entitled *International Agency for Research on Cancer: The First 50 Years, 1965–2015*. The achievements documented there have been realized in major part by an adherence to the original vision for the Agency; namely, to promote collaboration with our colleagues worldwide to achieve a shared goal of reducing the heavy burden that cancer places on humanity. As a part of this vision, IARC is also pleased to launch at this conference a unique initiative, entitled “50 for 50”. Fifty emerging cancer research leaders have been invited to attend the conference, to participate in leadership training events, to meet with each other and with world-leading cancer researchers. Please look out for them, welcome them and encourage them.

From the earliest days of the Agency, IARC scientists have sought to understand the causes of cancer through the study of international variations in incidence. The geographical variations also implicitly pointed to opportunities for prevention, by avoiding or reducing exposure to risk factors. IARC’s Monographs Programme on the evaluation of carcinogenic risks to humans has established itself as the definitive global source for the categorization of cancer-causing agents. IARC has also worked to evaluate preventive interventions, stretching beyond primary prevention into the areas of early detection and screening. The Agency’s research was pioneering in its interdisciplinary nature, encompassing epidemiology, biostatistics, laboratory sciences and, more recently, bioinformatics.

When the Agency began its work, no one knew which genes were the targets of alteration by environmental risk factors, contributing to key changes in cancer pathways and the genesis of a tumour. Today, whole-genome sequencing reveals somatic mutation spectra, which themselves are potential sources of information about the etiological origins of a cancer. Sadly, while the understanding of cancer risk factors and of the underlying molecular biology of cancer is unrecognizable compared with 50 years ago, in stark contrast, many of the global disparities in cancer incidence and outcomes, evident to IARC scientists in the mid-1960s, are still all too easily recognizable today.

IARC remains committed to research on the global burden, causes and prevention of cancer. Thus, it is no accident that the scope of this international conference mirrors that commitment. The number of cancer patients and the costs of care are spiralling, nowhere more so than in the low- and middle-income countries where cancer is a barrier to human development. In the face of these challenges, cancer prevention and early detection must be the complement of cancer treatment. There is a duty of care to the patients of today but also to the populations of tomorrow. International collaboration is a key to our collective response as a research community, and IARC will play its part as it moves into its second 50 years.

I wish all participants, coming from all over the world, an inspiring few days in Lyon. The range of countries represented is in some ways a perfect testimony to what is at the heart of the Agency: international cooperation to generate the scientific evidence base for cancer control. The new relationships formed and the existing ones strengthened during this conference will constitute a firm foundation for this goal. There could be no more fitting legacy from the first 50 years of the International Agency for Research on Cancer.

Table of contents

International Agency for Research on Cancer	6
IARC Medals of Honour	9
IARC “50 for 50” Initiative	10
Scientific Committees	11
WEDNESDAY 8 JUNE 2016	
Plenary Sessions	12
Parallel Sessions - 14:40 – 15:40	13
Parallel Sessions - 16:00 – 17:00	14
Invited Speakers	15
THURSDAY 9 JUNE 2016	
Plenary Sessions	20
Parallel Sessions - 11:00 – 12:00	21
Parallel Sessions - 14:30 – 15:30	22
Parallel Sessions - 16:00 – 17:00	23
Invited Speakers	24
FRIDAY 10 JUNE 2016	
Plenary Sessions	28
Parallel Sessions - 11:00 – 12:00	29
Invited Speakers	30
Poster Sessions	34
Satellite Meetings	36
Practical Information	40

International Agency for Research on Cancer



The International Agency for Research on Cancer (IARC) was established in May 1965 as an autonomous specialized agency of the World Health Organization (WHO), with the mission of promoting international collaboration in cancer research.

The Agency's research is interdisciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to study the causes of cancer, the mechanisms of carcinogenesis and cancer prevention interventions, providing the evidence base for the development of effective strategies to reduce the global cancer burden.

IARC's worldwide mandate and independent role as an international organization enable the efficient coordination of international collaborative research projects involving large networks of organizations. In addition, the privileged relationship with WHO supports the rapid translation of research findings into policies and recommendations.

IARC has a long-standing commitment to promoting research in low- and middle-income countries (LMICs), through partnerships and collaborations with local institutions and researchers. Another principle of the Agency's approach is the commitment to training the next generations of cancer researchers, through education and training programmes integrated into its research activities.

As well as conducting original research that is broadly acknowledged for its high quality and independence, IARC produces some of the most authoritative and widely used global reference sources on cancer, such as the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; the IARC Handbooks of Cancer Prevention; the WHO Classification of Tumours, or "WHO Blue Books"; and global cancer statistics databases such as GLOBOCAN and Cancer Incidence in Five Continents. In addition, IARC hosts a number of valuable resources for cancer research, such as the IARC Biobank, one of the largest and most varied international collections of its type, which presently holds more than 5 million well-characterized biological samples, from over 560 000 individuals worldwide.



IARC PARTICIPATING STATES

IARC's activities are supported and overseen by its Participating States. Currently there are 25 Participating States (listed below), which support IARC's global mission by advising on research priorities and by contributing resources and expertise to its programmes.

Current IARC Participating States:

Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, India, Ireland, Italy, Japan, Morocco, Netherlands, Norway, Qatar, Republic of Korea, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom and United States of America.



The following sections provide a brief outline of IARC's core areas of activity.

Describing the occurrence of cancer

Access to reliable cancer statistics is essential to support the development of effective cancer prevention and control programmes, highlighting priorities for action and enabling the evaluation of cancer control interventions. Monitoring the worldwide cancer burden has been one of the priority areas of the Agency's work since its creation, providing accurate data on cancer incidence, prevalence, mortality and survival, and conducting original research on descriptive epidemiology of cancer, analysing geographical variations and trends over time.

Understanding the causes of cancer

Despite advances in the identification of the causes of human cancers, there remain a large proportion for which etiology is unclear. Epidemiological research on cancer etiology and laboratory-based research on the cellular and molecular mechanisms of carcinogenesis are among the largest areas of activity at IARC, involving a number of research groups. These complementary approaches provide fundamental insights into the interaction between genetic, environmental, infectious and lifestyle factors that result in the development of cancer, which in turn offer new opportunities for the development of novel strategies for prevention and treatment.




IARC MONOGRAPHS

The Monographs Programme is IARC's international, interdisciplinary approach to carcinogenic hazard identification, which is regarded as the definitive reference in this area. The IARC Monographs provide national and international health agencies with authoritative and independent scientific evidence to support and inform their cancer prevention programmes. To date almost 1000 agents have been evaluated, with nearly half classified as *carcinogenic*, *probably carcinogenic*, or *possibly carcinogenic to humans*.

Evaluating cancer prevention strategies and their implementation

The evaluation of interventions for cancer prevention is of fundamental importance to the Agency as it represents the translation of insights from research in other areas into concrete approaches for reducing the burden of cancer. The focus at IARC is on research evaluating the safety and effectiveness of prevention, screening and early detection methods for cancers common in LMICs, complemented by research on factors affecting their successful implementation and scale-up in routine health services. The results support the development of cost-effective, evidence-based prevention and early detection programmes in developing countries, with built-in quality assurance, monitoring and evaluation mechanisms.

International Agency for Research on Cancer



WHO Classification of Tumours

The WHO Classification of Tumours series – the WHO “Blue Books” – is the definitive reference in pathological and genetic classification and grading of human tumours. Accurate tumour classification is essential for cancer surveillance, clinical practice and research, and this series is a leading example of international cooperation by IARC.



IARC Handbooks

The IARC Handbooks of Cancer Prevention, a complementary programme to the IARC Monographs, undertakes comprehensive, critical reviews of the published scientific evidence on the effectiveness of individual agents and primary and secondary interventions for cancer prevention. The IARC Handbooks

have a direct impact, supporting the development of evidence-based public health guidelines, recommendations, and cancer prevention policies.



International Agency for Research on Cancer: The First 50 Years, 1965–2015

Authors: Saracci R and Wild CP

This book charts the birth of IARC during the 1960s, a period of great optimism for international cooperation and medical science, and goes on to describe the Agency's major achievements over the past five decades. By examining IARC's history, the authors illustrate how,

despite the changing landscape of cancer research, the original vision continues to be a valid response to the needs for cancer prevention and control worldwide today.



World Cancer Report 2014

Editors: Stewart BW and Wild CP
World Cancer Report provides a unique global view of cancer, including cancer patterns, causes, and prevention. The *World Cancer Report* series is recognized as an authoritative source of global perspective and information on cancer. The first volume appeared in 2003 and the second in 2008.

This third volume in the series encompasses both established knowledge and recent research developments.



Global Cancer Observatory (GCO)

IARC has developed the Global Cancer Observatory (GCO, <http://gco.iarc.fr/>), an interactive web-based platform incorporating global cancer statistics to inform cancer control and cancer research. Based on key projects within the IARC Section of Cancer Surveillance – including GLOBOCAN, Cancer Incidence in Five Continents (CI5), International Incidence of Childhood Cancer (IICC) and Cancer Survival in Africa, Asia, the Caribbean and Central America (SURVCAN) – the GCO will also link to related activities in the Section, including research that documents global cancer transitions and efforts through the Global Initiative for Cancer Registry Development (GICR, <http://gicr.iarc.fr/>), a multi-partner initiative led by IARC to improve the accuracy and coverage of cancer data worldwide by supporting countries to develop high-quality cancer registries.

IARC Medals of Honour

The IARC Medals of Honour are awarded to acknowledge and reward the work of scientists who have made an outstanding contribution to cancer research. Each year IARC invites two of the most influential leaders in the study of the biology or of the epidemiology of cancer to give a keynote lecture, and each speaker is presented with an IARC Medal of Honour.

On the occasion of IARC's 50th anniversary scientific conference, the IARC Medals of Honour will be awarded to Elizabeth Blackburn, President of the Salk Institute for Biological Studies, and Lynette Denny, Chair and Professor of Obstetrics & Gynaecology at Groote Schuur Hospital and the University of Cape Town. During the conference, Elizabeth Blackburn will present her research on "Telomeres, biology and cancer", and Lynette Denny will present her work on "Screening and early detection of cervical cancer in Africa".



2016 IARC MEDALS OF HONOUR LAUREATES



Elizabeth Blackburn

President of the Salk Institute for Biological Studies, La Jolla, USA – Nobel Prize laureate in Physiology or Medicine 2009

> See biography on page 17

Plenary session: "Telomeres, biology and cancer"

Wednesday 8 June, 17:10 – 17:40
in Amphithéâtre 3000



Lynette Denny

Chair and Professor of Obstetrics & Gynaecology and registered sub-specialist in Gynaecological Oncology at Groote Schuur Hospital and the University of Cape Town, South Africa

> See biography on page 24

Plenary session: "Screening and early detection of cervical cancer in Africa"

Thursday 9 June, 10:00 – 10:30
in Amphithéâtre 3000

IARC “50 FOR 50” INITIATIVE

Empowering future cancer research leaders

An initiative within the conference on Global Cancer: Occurrence, Causes, and Avenues to Prevention

Lyon, 6–10 June 2016

The IARC “50 for 50” initiative is a fellowship programme bringing together, in Lyon, 50 future leaders in cancer research from low- and middle-income countries, one for each year of IARC’s existence. The one-week programme includes participation in the three-day scientific conference for IARC’s 50th anniversary, a pre-conference workshop, and a series of networking events to foster collaborations.

The workshop comprises a blend of plenary and group sessions structured around the concept of a Leadership Toolbox:

- Infrastructure needs for a cancer research centre: challenges and solutions for the development or strengthening of a multidisciplinary and collaborative cancer research institute that supports the national and global health agenda.
- Networking in research: how to create a network, how to build a collaborative research team, how to strengthen the team dynamics, etc.
- Safeguarding research and research participants: confidentiality/data protection, ethical and legal issues of observational and interventional studies, ethics committees, managing conflicts of interest, etc.
- Funding: determinants of success for fundraising through competitive grants (mining the global funding landscape, applying thorough grantsmanship for grant writing, etc.).

In addition, a variety of learning resources on leadership, management, and communication skills will be accessible.

The programme has been tailored according to the profile and needs of the participants and will maximize the opportunities for participants to network.

The 50 highly qualified participants coming from across the globe and representing 36 countries* will share their experience during this initiative.

Support from the following is acknowledged:

American Society for Clinical Oncology – Asian Fund for Cancer Research – Chinese Anti-Cancer Association – European Association for Cancer Research – European School of Oncology – French Ligue Nationale Contre le Cancer – Métropole de Lyon – Ministry of Health, Germany – Ministry of Health, Russian Federation – Swiss Cancer League – Swiss Cancer Research Foundation

* Albania, Armenia, Bangladesh, Brazil, Bulgaria, Cameroon, China, Colombia, Costa Rica, Croatia, Egypt, El Salvador, Ghana, India, Indonesia, Islamic Republic of Iran, Kenya, Lebanon, Malawi, Mali, Morocco, Myanmar, Nepal, Nigeria, Pakistan, Paraguay, Peru, South Africa, Sudan, United Republic of Tanzania, Thailand, Turkey, Uganda, Ukraine, Zambia, and Zimbabwe.

Scientific Committees

INTERNATIONAL SCIENTIFIC ADVISORY COMMITTEE

Bruce Armstrong, University of Sydney, Australia
Agnès Buzyn, Institut National du Cancer (INCa), Boulogne-Billancourt, France
Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Stephen Chanock, United States National Cancer Institute, Bethesda, USA
Adèle Green, QIMR Berghofer Medical Research Institute, Brisbane, Australia
Paul Kleihues, Faculty of Medicine, University of Zurich, Switzerland
Tezer Kutluk, Union for International Cancer Control (UICC) and Hacettepe University, Ankara, Turkey
Gilbert Lenoir, Institut Gustave Roussy, Villejuif, France
Nubia Muñoz, Lyon, France
Hitoshi Nakagama, National Cancer Center, Tokyo, Japan
Richard Peto, University of Oxford, United Kingdom
Alain Puisieux, Centre de Recherche en Cancérologie de Lyon, France
You-Lin Qiao, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Luiz Santini, Network of National Cancer Institutes in South America (RINC), Rio de Janeiro, Brazil
Michael Thun, American Cancer Society, Atlanta, USA
Edward Trimble, United States National Cancer Institute, Rockville, USA
Cornelia Ulrich, Huntsman Cancer Institute, Salt Lake City, USA
Harri Vainio, Finnish Institute of Occupational Health, Helsinki, Finland
Flora van Leeuwen, Netherlands Cancer Institute, Amsterdam, Netherlands
Paolo Vineis, Imperial College London, United Kingdom
Otmar D. Wiestler, Helmholtz Association, Berlin, Germany
Harald zur Hausen, German Cancer Research Center (DKFZ), Heidelberg, Germany

IARC SCIENTIFIC ORGANIZING COMMITTEE

Anouk Berger, Head, Education and Training Group
Paul Brennan, Head, Section of Genetics
David Forman, Senior Visiting Scientist (Chair)
Joachim Schüz, Head, Section of Environment and Radiation
Eduardo Seleiro, Scientific Officer, Office of the Director
Christopher P. Wild, Director
Jiri Zavadil, Head, Molecular Mechanisms and Biomarkers Group

IARC ORGANIZING TEAM

Natasha Blavoyer, Coordinator (until February 2016), **David Forman**, Senior Visiting Scientist, **Nicolas Gaudin**, Head, Communications Group, **Raphaël Pin**, Insight Outside, **Sophie Servat**, Coordinator, Logistics & Practical Arrangements, **Aurélien Viotto**, Coordinator, Event & Communications

THANKS TO THE SUPPORT RECEIVED FROM:

IARC staff members: Sébastien Agathe, Christopher Jack, Fabienne Lelong, Sylvia Lesage, Laurence Marnat, Sandrine Montigny, Karen Müller, Editta Odame, Andreea Spanu, Nicolas Tardy, Véronique Terrasse.

Our volunteer team of early career scientists: Devasena Anantharaman, Raquel Aparicio Ugarriza, Maude Ardin, Patrice Avogbe, Anya Burton, Alessandra Campese, Tiffany Delhomme, Sankhadeep Dutta, Szilvia Ecsedi, Eleonora Feletto, Aida Ferreira, Tomoko Inamasu, Rim Khelifi, Ivana Kulhanova, Ruhina Laskar, Noémie Leblay, Peng Li, Chunqing Lin, Sengkwawoh Lueong Smiths, Claire Marant-Micallef, Marco Matejcic, Michele Matta, Amy Mullee, Manuraj Pandey, Marta Pittavino, Fazlur Rahman Talukdar, Claudia Robles, Kayo Togawa, Stephen Tully, Sahar Yammine, Maria Zhivagui.

Our team of abstract reviewers: Rosita Accardi, Maribel Almonte, Maude Ardin, Partha Basu, Freddie Bray, Lynette Cuesta, Gary Clifford, Isabelle Deltour, Pietro Ferrari, Matthieu Foll, Silvia Franceschi, Akram Ghantous, Kate Guyton, Neela Guha, Zdenko Herczeg, Rolando Herrero, Mazda Jenab, Mattias Johansson, Ausrele Kesminiene, Béatrice Lauby-Secretan, Maria Leon-Roux, Dana Loomis, Valerie McCormack, James McKay, Fiona McKenzie, Les Mery, Raúl Murillo, Wynne Norton, Magali Olivier, Ann Olsson, Evgeniya Ostroumova, Sabina Rinaldi, Isabelle Romieu, Rengaswamy Sankaranarayanan, Catherine Sauvaget, Augustin Scalbert, Isabelle Soerjomataram, Kurt Straif, Massimo Tommasino, Salvatore Vaccarella, Hector Vargas, Patricia Villain, Hugo de Vuyst, Jiri Zavadil.

Plenary Sessions

Wednesday 8 June 2016 - Amphithéâtre 3000

Wednesday 8 June 2016

8:30 – 9:10	Opening Ceremony
Chairs: Christopher P. Wild , IARC, Lyon, France & Helen Zorbas , Cancer Australia, Sydney, Australia	
9:10 – 9:40	Christopher P. Wild , IARC, Lyon, France <i>IARC: 50 years of cancer research for cancer prevention</i>
9:40 – 10:00	HRH Princess Dina Mired , King Hussein Cancer Foundation, Amman, Jordan <i>Caring about cancer</i>
10:00 – 10:30	Douglas Lowy , United States National Cancer Institute, Bethesda, USA <i>The potential of cost-effective precision medicine in the low- and middle-income countries</i>
10:30 – 11:00	Coffee break - Level –2
Chairs: Silvia Franceschi , IARC, Lyon, France & Tezer Kutluk , Union for International Cancer Control and Hacettepe University, Ankara, Turkey	
11:00 – 11:30	Freddie Bray , IARC, Lyon, France <i>The global burden of cancer</i>
Chair: Mary Gospodarowicz , Princess Margaret Cancer Centre, Toronto, Canada	
11:30 – 12:15	Panel Debate 1 Cancer research investment should shift from late-stage treatment to early-stage detection Pro: Rengaswamy Sankaranarayanan , IARC, Lyon, France Anti: Soo Khee Chee , National Cancer Centre Singapore
12:15 – 14:00	Lunch break and Poster session - Level –2
Chairs: Paul Brennan , IARC, Lyon, France & Alain Puisieux , Centre de Recherche en Cancérologie de Lyon, France	
14:00 – 14:30	Michael Stratton , Wellcome Trust Sanger Institute, Cambridge, United Kingdom <i>Signatures of mutational processes in human cancer</i>
14:40 – 15:40	Parallel Sessions (details on page 13)
15:40 – 16:00	Coffee break - Level –2
16:00 – 17:00	Parallel Sessions (details on page 14)
Chairs: Christopher P. Wild , IARC, Lyon, France & Frédéric Biemar , American Association for Cancer Research, Philadelphia, USA	
17:10 – 17:40	Recipient of 2016 IARC Medal of Honour Elizabeth Blackburn , Salk Institute for Biological Studies, La Jolla, USA The American Association for Cancer Research Lecture <i>Telomeres, biology and cancer</i>
Chairs: Christopher P. Wild , IARC, Lyon, France & Xishan Hao , Chinese Anti-Cancer Association, Tianjin, China	
17:40 – 18:10	David Hunter , Harvard T.H. Chan School of Public Health, Boston, USA <i>Cancer, NCDs and global health</i>

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Wednesday 8 June 2016 - 14:40 – 15:40

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Global burden of cancer and cancer registries

Chairs: **Freddie Bray**, IARC, Lyon, France & **Roberto Zanetti**, International Association of Cancer Registries and Piedmont Cancer Registry, Turin, Italy

Speakers:

1. **Florence Tangka (USA):** Resource requirements for cancer registration: comparative cost data from five countries
2. **Les Mery (IARC):** Building capacity for cancer control research: the Global Initiative for Cancer Registry Development (GICR)
3. **Morten Valberg (Norway):** Prostate-specific antigen testing for prostate cancer: emptying a pool of susceptible individuals?
4. **Kazem Zendehehdel (Islamic Republic of Iran):** Initiative for semi-automated population-based cancer registry in Iran
5. **Salvatore Vaccarella (IARC):** The impact of diagnostic changes on the rise in thyroid cancer incidence

MECHANISMS in Tête d'Or Room (level 1)

Theme: Systems perspectives of the exposome

Chairs: **Jiri Zavadil**, IARC, Lyon, France & **Paolo Vineis**, Imperial College London, United Kingdom

Invited Speaker: **Paolo Vineis**, Imperial College London, United Kingdom
"Systems perspectives of the exposome"

Speakers:

1. **Roel Vermeulen (Netherlands):** A systematic comparison of linear regression-based statistical methods to assess exposome-health associations
2. **Silvia Balbo (USA):** DNA adductomics for the investigation of alcohol-related DNA damage
3. **Ludmil Alexandrov (USA):** The pathogenesis of increased cancer risk due to tobacco smoking

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Challenges in primary prevention

Chairs: **Partha Basu**, IARC, Lyon, France & **Adèle Green**, QIMR Berghofer Medical Research Institute, Brisbane, Australia

Invited Speaker: **Adèle Green**, QIMR Berghofer Medical Research Institute, Brisbane, Australia
"Challenges in primary prevention"

Speakers:

1. **Shao-Ming Wang (China):** Long-term risk of upper digestive cancer in people with different baseline characteristics and supplementation with various combinations of multivitamins and minerals: 27-year follow-up results from the Linxian Nutrition Intervention Trial
2. **Montserrat Garcia-Closas (USA):** Development and validation of a synthetic risk model for stratified disease prevention for breast cancer
3. **Laia Bruni (Spain):** Worldwide HPV vaccination coverage for cervical cancer prevention

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Wednesday 8 June 2016 - 16:00 – 17:00

Wednesday 8 June 2016

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Tobacco and alcohol in cancer

Chairs: **Paul Brennan**, IARC, Lyon, France & **Stephen Hecht**, University of Minnesota, Minneapolis, USA

Speakers:

1. **Diana Menya (Kenya):** Esophageal cancer case-control study in western Kenya – do alcohol and tobacco contribute?
2. **Inger Gram (Norway):** The fraction of breast cancer attributable to smoking in Norway in 2012. The Norwegian Women and Cancer Study 1991–2012
3. **Sreenath Madathil (Canada):** Life-course trajectories of tobacco and alcohol consumption and risk of head and neck cancer; does human papillomavirus play a role? An international multi-center study
4. **Licaj Idlir (Norway):** Smoking and risk of epithelial ovarian cancer subtypes in three prospective cohort studies
5. **David Zaridze (Russian Federation):** Relevance of alcohol and tobacco to high premature mortality rate in Russia: prospective study of 200 000 adults

MECHANISMS in Tête d'Or Room (level 1)

Theme: Mechanisms in carcinogen evaluation

Chairs: **Kurt Straif**, IARC, Lyon, France & **Martyn Smith**, School of Public Health, University of California, Berkeley, USA

Invited Speakers: **Martyn Smith**, School of Public Health, University of California, Berkeley, USA
“The key characteristics of human carcinogens”

Sarah Lewis, University of Bristol, United Kingdom

“Linking diet, nutrition and physical activity to cancer: a systematic review framework for integrating evidence from human, animal and other mechanistic studies”

Speakers:

1. **Weihshueh Chiu (USA):** Use of high-throughput screening data in IARC Monographs evaluations
2. **Emmanuel Farge (France):** Mechanical induction of the tumorigenic-catenin pathway by tumour growth pressure

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Screening and early detection

Chairs: **Rengaswamy Sankaranarayanan**, IARC, Lyon, France & **You-Lin Qiao**, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Invited Speaker: **You-Lin Qiao**, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
“Experience with careHPV implementation in China”

Speakers:

1. **Fabio Barbone (Italy):** The mortality for lung cancer is reduced in a low-dose CT scan screening program compared with conventional public health surveillance for former workers exposed to asbestos
2. **Louise Brinton (USA):** Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa
3. **Mattias Johansson (IARC):** Comprehensive evaluation of promising biomarkers for lung cancer risk prediction

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Wednesday 8 June 2016



Christopher P. Wild

Director, International Agency for Research on Cancer, Lyon, France

Christopher Paul Wild obtained his PhD in 1984 from the University of Manchester, United Kingdom, while working on DNA damage and repair. He was awarded a postdoctoral fellowship from the International Agency for Research on Cancer (IARC) to work in Lyon, France, and subsequently a United Kingdom Royal Society European Exchange Fellowship to spend a year at the Netherlands Cancer Institute in Amsterdam. In 1987, Dr Wild re-joined IARC as a staff scientist and later became Chief of the Unit of Environmental Carcinogenesis. In 1996, he was appointed to the Chair of Molecular Epidemiology at the University of Leeds, was Head of the Centre for Epidemiology and Biostatistics and later became Director of the Leeds Institute of Genetics, Health and Therapeutics in December 2005. Dr Wild was elected Director of IARC from 1 January 2009. His main research interest is to understand the interplay between environmental and genetic risk factors in the causation of human cancer. He has particularly sought to apply biomarkers in population-based studies to this end. His specific areas of research have been focused on liver and oesophageal cancers.

Plenary session: "IARC: 50 years of cancer research for cancer prevention"

Room: Amphithéâtre 3000 / 9:10 – 9:40



HRH Princess Dina Mired

Director General, King Hussein Cancer Foundation and Honorary Chairperson of the Jordan Breast Cancer Program, Amman, Jordan

HRH Princess Dina Mired has led the King Hussein Cancer Foundation (KHCF) in Jordan as Director General since 2002. In that capacity, she founded, developed and institutionalized the fundraising and development function and programs at the Foundation, which is now the largest source of non-profit funds dedicated to fighting cancer in Jordan. Under her direct leadership, KHCF has succeeded in enlisting all segments of society in the fight against cancer with the sole purpose of supporting cancer patients in Jordan and the Arab world. HRH Princess Dina Mired is also the Honorary Chairperson of the Jordan Breast Cancer Program (JBCP). As a global advocate, HRH Princess Dina Mired delivered the keynote speech on behalf of all civil society (social, civic and voluntary organizations) at the September 2011 opening of the United Nations General Assembly High-Level Meeting on Non-Communicable Diseases (NCDs); HRH Princess Dina Mired is also an Honorary Co-President of the Harvard University Global Task Force for Expanded Access to Cancer Care and Control in the Developing World. She is also a member of the Presidential Advisory Panel of the Union for International Cancer Control (UICC).

Plenary session: "Caring about cancer"

Room: Amphithéâtre 3000 / 9:40 – 10:00



Douglas Lowy

Acting Director of the United States National Cancer Institute (NCI) and Chief of the intramural Laboratory of Cellular Oncology in the Center for Cancer Research at the NCI, Bethesda, USA

Douglas Lowy received his medical degree from the New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale University. His research includes papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with John Schiller, with whom he has co-authored more than 100 papers over the past 25 years. In the 1980s, he studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. More recently, he has worked on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that have been approved by the United States Food and Drug Administration and many other countries. It is for this body of work that Drs Lowy and Schiller received the 2007 Federal Employee of the Year Award from the Partnership for Public Service, the 2007 Dorothy P. Landon-American Association for Cancer Research Prize for Translational Cancer Research, the Sabin Gold Medal in 2011, and the National Medal of Technology and Innovation from President Obama in 2014. Dr Lowy also received the 2007 Medal of Honor for basic research from the American Cancer Society. He is listed by the Institute for Scientific Information as one of the most highly cited authors in microbiology, and is a member of the National Academy of Sciences (NAS) and the Institute of Medicine of the NAS.

Plenary session: "The potential of cost-effective precision medicine in the low- and middle-income countries"

Room: Amphithéâtre 3000 / 10:00 – 10:30

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Wednesday 8 June 2016

Wednesday 8 June 2016



Freddie Bray

Head, Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France

Freddie Bray has a PhD in Epidemiology from the London School of Hygiene and Tropical Medicine, and degrees in Statistics from the University of Aberdeen and Medical Statistics from the University of Leicester, United Kingdom. He has worked previously at IARC from 1998 to 2005 and at the Cancer Registry of Norway and the University of Oslo from 2005 to 2010. His areas of research revolve around the descriptive epidemiology of cancer, including the estimation of the global cancer burden and the analysis of time trends, including global predictions of the future scale and profile of cancer linked to human development transitions. He has close to 200 book chapters and articles in journals including *The Lancet*, *The Lancet Oncology*, *JNCI* and *Nature Reviews Cancer*. In support of the overwhelming need for high-quality cancer surveillance systems given their current paucity and an ever-increasing cancer problem, Dr Bray leads the Global Initiative for Cancer Registry Development (<http://gicr.iarc.fr>), an international multi-partner programme designed to ensure a sustainable expansion of the coverage and quality of population-based cancer registries in low- and middle-income countries through tailored, localized support and advocacy to individual countries.

Plenary session: "The global burden of cancer"

Room: Amphithéâtre 3000 / 11:00 – 11:30



Rengaswamy Sankaranarayanan

Special Advisor on Cancer Control and Head of the Screening Group, International Agency for Research on Cancer, Lyon, France

Rengaswamy Sankaranarayanan has an MD degree in radiation oncology, followed by postdoctoral training at the University of Pittsburgh and the University of Cambridge. After several years of experience in clinical oncology and cancer control in India, Dr Sankaranarayanan joined the International Agency for Research on Cancer in 1993. Through the IARC Screening Group, and through innovative partnerships with other international organizations, national institutions and investigators, Dr Sankaranarayanan is involved in conducting several studies worldwide with the aim of providing scientific evidence to support the development of appropriate public health policies of screening for common cancers in a range of health care settings, particularly in low- and middle-income countries. These studies provide valuable data on the accuracy, reproducibility, efficacy, benefits, harmful effects and cost-effectiveness of different screening interventions for cervical, oral, colorectal and breast cancers, leading to the rational utilization of health care resources in the design, implementation, monitoring and evaluation of screening programmes. Dr Sankaranarayanan has a strong commitment to research, training, programme development and technical assistance in the early detection and control of cancer, particularly breast, cervical, colorectal and oral cancers in low- and middle-income countries. He has taught as a faculty member in over 40 international courses on cervical cancer screening, colposcopy, diagnosis and treatment of cervical neoplasia, cancer registry epidemiology and cancer control. He is also an author on more than 240 papers in international peer-reviewed journals, and his manuals on early detection of cervical cancer have been translated into several languages.

Soo Khee Chee

Director, National Cancer Centre Singapore, Senior Vice Dean (Clinical, Academic and Faculty Affairs), Duke-NUS Graduate Medical School and Deputy Group CEO (Research and Education), Singapore Health Services, Singapore



Dr Soo Khee Chee is a surgical oncologist. He is still in active practice. He is the founding Director of the National Cancer Centre Singapore. This centre treats about half of all cancer patients in the country. Additional administrative responsibilities include being the Senior Vice Dean of Clinical, Academic and Faculty Affairs of the Duke-NUS Graduate Medical School, and Deputy Group Chief Executive Officer of Research and Education for the largest health cluster in Singapore: the Singapore Health Services.

Panel debate: "Cancer research investment should shift from late-stage treatment to early-stage detection"

Room: Amphithéâtre 3000 / 11:30 – 12:15

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Wednesday 8 June 2016



Michael Stratton

Director, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Michael Stratton's primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. He mapped and identified the major high-risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate-risk breast cancer and other cancer susceptibility genes. In 2000 he initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute, which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes, revealing underlying DNA mutational and repair processes. He is a Fellow of the Royal Society (FRS) and was knighted by the Queen in 2013.

Plenary session: "Signatures of mutational processes in human cancer"

Room: Amphithéâtre 3000 / 14:00 – 14:30



Elizabeth Blackburn, Recipient of 2016 IARC Medal of Honour

President of the Salk Institute for Biological Studies, La Jolla, USA

Elizabeth Blackburn became President of the Salk Institute for Biological Studies on 1 January 2016. Dr Blackburn is a pioneering molecular biologist. Since 2001 she had served as a Salk Non-Resident Fellow while she was a Professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr Blackburn won the Nobel Prize in Physiology or Medicine in 2009 for discovering the molecular nature of telomeres, the ends of chromosomes that serve as protective caps essential for preserving genetic information, and for co-discovering telomerase, an enzyme that maintains telomere ends. Both telomeres and telomerase are thought to play central roles in ageing and diseases such as cancer, and her work helped launch entire new fields of research. In addition to the Nobel Prize, Dr Blackburn has received nearly every major award in science, including the Lasker, Gruber, and Gairdner prizes. In 2007, she was named one of *Time* magazine's 100 most influential people in the world. She is a member of numerous prestigious scientific societies, including the National Academy of Sciences, the National Academy of Medicine, and the Royal Society of London. She has served as president of both the American Association for Cancer Research and the American Society for Cell Biology, and has served on the editorial boards of several journals, including *Cell* and *Science*. Helping to guide public science policy, she was a member of the Stem Cell Research Advisory Panel for the California State Legislature and a member of the President's Council of Bioethics, an advisory committee to the President of the USA.

Plenary session: "Telomeres, biology and cancer"

Room: Amphithéâtre 3000 / 17:10 – 17:40



David Hunter

Acting Dean, Vincent L. Gregory Professor of Cancer Prevention, Harvard T.H. Chan School of Public Health, Boston, USA

David Hunter's principal research interests are the etiology of cancer, particularly breast, prostate, pancreas and skin cancers. He analyzes inherited susceptibility to cancer and other chronic diseases using molecular techniques and gene-environment interactions. This work is largely based in subcohorts of the Nurses' Health Study and the Health Professionals Follow-up Study. Dr Hunter supervised laboratories at the Harvard School of Public Health in which gene sequence information from these samples is obtained. Dr Hunter has also studied HIV transmission for over 20 years, initially in Kenya and then in Tanzania. He has collaborated with investigators in Dar es Salaam to understand the relationship of nutritional status to progression of HIV disease and perinatal transmission. Professor Hunter was the Director of the Harvard Center for Cancer Prevention from 1997 to 2003. In June 2009, he was appointed Dean for Academic Affairs at the School. He is also the Vincent L. Gregory Professor of Cancer Prevention. He is the founding Director of HSPH's Program in Molecular and Genetic Epidemiology and is Principal Investigator of a number of ongoing breast and prostate cancer studies. He co-chaired the Steering Committee of the National Cancer Institute (NCI) Breast and Prostate Cancer Cohort Consortium, was co-Director of the NCI Cancer Genetic Markers of Susceptibility (CGEMS) Special Initiative, and was a member of the Board of Scientific Counselors of the NCI. He is Contact Principal Investigator of the DRIVE (Discovery, Biology and Risk of Inherited Variants in Breast Cancer) Consortium.

Plenary session: "Cancer, NCDs and global health"

Room: Amphithéâtre 3000 / 17:40 – 18:10

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Wednesday 8 June 2016

Wednesday 8 June 2016



Paolo Vineis

Chair in Environmental Epidemiology, Centre for Environment and Health, School of Public Health, Imperial College London, United Kingdom

Paolo Vineis is a leading researcher in the fields of molecular epidemiology and exposomics. His latest research activities mainly focus on examining biomarkers of disease risk, complex exposures and intermediate biomarkers from omic platforms (including metabolomics and epigenetics) in large epidemiological studies as well as studying the effects of climate change on noncommunicable diseases. He has more than 700 publications (many as leading author) in journals such as *Nature*, *Nature Genetics*, *The Lancet* and *The Lancet Oncology*. He is a member of various international scientific and ethics committees (including the Committee of the United States National Academy of Sciences on 21st Century Risk Assessment) and Vice-Chair of the Ethics Committee at the International Agency for Research on Cancer. He has been a member of the Scientific Council of IARC. Professor Vineis has extensive experience in leading international projects. He is currently the coordinator of the European Commission-funded Exposomics project (valued at €8.7m, started in 2012) and the Horizon 2020-funded project Lifepath (valued at €6m, started in 2015). He is a Principal Investigator/Co-investigator of numerous international research projects, such as the European Commission-funded GENAIR, ECNIS2, Envirogenomarkers, Hypergenes, ESCAPE and Transphorm networks, in which he has led Work Packages. In addition, he has attracted grants from the Leverhulme Trust, MRC, Cancer Research UK, HuGeF Foundation and the United States National Cancer Institute. He is the director of the Unit of Molecular and Genetic Epidemiology, HuGeF Foundation, Turin, Italy and leads the Exposure and Health theme of the MRC-PHE Centre for Environment and Health at Imperial College.

Parallel session: "Systems perspectives of the exposome"

Room: Tête d'Or (level 1) / 14:40 – 15:40



Adèle Green

Senior Scientist at QIMR Berghofer Medical Research Institute, Brisbane, Australia and Senior Research Scientist at Cancer Research UK Manchester Institute, United Kingdom

Adèle Green is a Senior Scientist at QIMR Berghofer Medical Research Institute in Brisbane, Australia (www.qimrberghofer.edu.au) and is a Senior Research Scientist at Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk) and Professor of Epidemiology at the University of Manchester (www.manchester.ac.uk). She trained in medicine, and her research career has focused on the causes, management and prevention of cancer, especially melanoma and other skin cancers, ovarian cancer and cancer in Aboriginal and Torres Strait Island people, for which she has received various awards. Her current research program includes studies of prevention of skin cancers in organ transplant recipients and survival and quality of life of patients with high-risk primary melanoma, as well as collaborative studies of gynaecological cancer, cancer risk prediction and clinicopathologic studies of melanoma. She has served on many IARC committees, including the Scientific Council, and is currently a member of the International Commission on Non-Ionizing Radiation Protection (ICNIRP), Chair of Cancer Australia's Research and Data Advisory Group, and a Member of the Australian Paediatric Cancer Registry Advisory Committee and the Australian Radiation Health and Safety Advisory Council.

Parallel session: "Challenges in primary prevention"

Room: Gratte-Ciel (level 2) / 14:40 – 15:40



Martyn Smith

Professor of Toxicology, Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, USA

Martyn Smith received his PhD in Biochemistry from St. Bartholomew's Hospital in London and did postdoctoral training in toxicology at the Karolinska Institute in Stockholm. Dr Smith has expertise in molecular epidemiology, toxicology and genomics, and his research is aimed at finding the causes of chronic diseases, including cancer and diabetes. He currently teaches Advanced Toxicology and mentors graduate students and postdoctoral scholars in the Molecular Toxicology, Epidemiology and Environmental Health programmes. Since 1987, he has been the Director of the NIEHS-funded UC Berkeley Superfund Research Program. The goals of this programme are to improve understanding of the relationship between exposure and disease; improve risk assessments; and develop prevention and remediation strategies to improve and protect public health and the environment. Dr Smith's current research is in the emerging field of exposomics, but he is perhaps best known for his research on benzene and blood cancers. He also works with international collaborators on using mechanistic data in the identification of human carcinogens. Dr Smith is a Fellow of the American Association for the Advancement of Science. He received the 2010 Children's Environmental Health Network Award, became an Elected Fellow of the Collegium Ramazzini in 2012, and received the Alexander Hollaender Award from the Environmental Mutagenesis and Genomics Society in 2014.

Parallel session: "Mechanisms in carcinogen evaluation"

Room: Tête d'Or (level 1) / 16:00 – 17:00

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Wednesday 8 June 2016



Sarah Lewis

Senior Lecturer in Genetic Epidemiology, University of Bristol, United Kingdom

Sarah Lewis obtained a BSc in Genetics at the University of Sheffield in 1995 and then went on to complete a PhD in Genetic Epidemiology at the University of Manchester in 1999. She then had a series of short postdoctoral positions, including a post at the International Agency for Research on Cancer. She joined the School of Social and Community Medicine in January 2004 as a Lecturer in Genetic Epidemiology and was promoted to Senior Lecturer in 2009. Her research interests are in using Mendelian randomization to understand risk factors for cancer and also to identify key nutrients required for in utero development. She is involved in a large United Kingdom-wide cohort study of cleft lip and palate, and a large birth cohort in which she is looking at the role of nutrition during pregnancy on childhood IQ and behaviour. She co-leads a work package on Mendelian randomization for the Integrative Cancer Epidemiology Programme, which is funded by Cancer Research UK. She is a Principal Investigator on a project to develop a framework for systematic reviews of mechanistic studies of diet and cancer in collaboration with the World Cancer Research Fund (WCRF). She also holds a grant from the WCRF to apply the above framework and Mendelian randomization to understanding the role of diet in prostate cancer.

Parallel session: "Mechanisms in carcinogen evaluation"

Room: Tête d'Or (level 1) / 16:00 – 17:00



You-Lin Qiao

Professor and Director, Department of Cancer Epidemiology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Before returning to China in 1997, You-Lin Qiao, MD, PhD, trained for 11 years at Johns Hopkins University School of Hygiene and Public Health and Cancer Prevention Studies Branch, NCI/NIH, USA. He is also Director of the International Collaboration Department, Cancer Foundation of China, and Deputy Director of the National Expert Committee for Cancer Screening and Prevention of the Ministry of Health in China. He is an author on over 480 peer-reviewed publications in both English and Chinese. As an expert in cancer prevention and control, he served in the WHO Director-General's Cancer Control Advisory Committee and WHO Cancer Technical Advisory Groups, helping to promote cancer prevention and control programmes in developing countries. He is involved in many national and international projects to study the etiology, primary intervention, and early detection of a variety of cancers through multidisciplinary and global collaborations. He was awarded the IARC Medal of Honour in 2011.

Parallel session: "Screening and early detection"

Room: Gratte-Ciel (level 2) / 16:00 – 17:00

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Plenary Sessions

Thursday 9 June 2016 - Amphithéâtre 3000

Wednesday 8 June 2016

Chairs: Joachim Schüz, IARC, Lyon, France & Gilbert Lenoir, Institut Gustave Roussy, Villejuif, France

9:00 – 9:30	Stephen Chanock , United States National Cancer Institute, Bethesda, USA Germline mutations
9:30 – 10:00	Valerie Beral , University of Oxford, United Kingdom The impact of tobacco, alcohol and hormones on women's cancers

Chairs: Christopher P. Wild, IARC, Lyon, France & Nubia Muñoz, Lyon, France

10:00 – 10:30	Recipient of 2016 IARC Medal of Honour Lynette Denny , University of Cape Town, South Africa Screening and early detection of cervical cancer in Africa
10:30 – 11:00	Coffee break - Level -2
11:00 – 12:00	Parallel Sessions (details on page 21)

Chair: Rodolfo Saracci, IARC, Lyon, France

12:10 – 12:55	Panel Debate 2 E-cigarettes represent a barrier to effective tobacco control Pro: Armando Peruga , World Health Organization, Geneva, Switzerland Anti: Jean-François Etter , University of Geneva, Switzerland
12:55 – 14:30	Lunch break and Poster session - Level -2
14:30 – 15:30	Parallel Sessions (details on page 22)
15:30 – 16:00	Coffee break - Level -2
16:00 – 17:00	Parallel Sessions (details on page 23)

Chairs: Rengaswamy Sankaranarayanan, IARC, Lyon, France & Vincent Coglian, United States Environmental Protection Agency, Washington DC, USA

17:10 – 17:40	Michael Marmot , University College London Institute of Health Equity, United Kingdom Reducing inequalities in risk
17:40 – 18:10	Graham Colditz , Washington University in St. Louis, USA Implementing strategies to prevent cancer
18:30 – 19:00	Jazz Concert in Amphithéâtre 3000 by the Big Band of the Regional Conservatory of Lyon (open to delegates and registered accompanying persons) 
19:30	Conference Dinner on Level -2

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Thursday 9 June 2016 - 11:00 – 12:00

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Nutrition, obesity and exercise

Chairs: **Marc Gunter**, IARC, Lyon, France & **Christine Friedenreich**, Cancer Control Alberta and University of Calgary, Canada

Invited Speakers: **Christine Friedenreich**, Cancer Control Alberta and University of Calgary, Canada
"Physical activity and cancer control: from observational to experimental evidence"

Michael Leitzmann, University of Regensburg, Germany

"Recent findings on diet, nutrition, physical activity and cancer: the WCRF/AICR continuous update project"

Speakers:

1. **Isabelle Romieu (IARC):** Risk factors for premenopausal breast cancer among Latin American women: the PRECAMA Study
2. **Gary Fraser (USA):** Diet and cancer in a U.S. cohort containing many vegetarians

MECHANISMS in Tête d'Or Room (level 1)

Theme: DNA damage, repair and mutagenesis

Chairs: **Massimo Tommasino**, IARC, Lyon, France & **Hitoshi Nakagama**, National Cancer Center, Tokyo, Japan

Invited Speaker: **Hitoshi Nakagama**, National Cancer Center, Tokyo, Japan

"Exploration of cancer etiology using whole genome/exome analysis and comprehensive DNA adduct analysis"

Speakers:

1. **Pratiek Matkar (Canada):** Novel regulatory role of BRCA2 in endothelial cell function and survival following genotoxic stress
2. **Abbas Karimi (Islamic Republic of Iran):** Exposure of hepatocellular carcinoma cells to low-level As₂O₃ causes an extra toxicity pathway via L1 retrotransposition induction
3. **Colinda Simons (Netherlands):** The joint value of microsatellite instability and the BRAF V600E mutation in colorectal cancer prognosis
4. **Janet Hall (France):** The role of PARP inhibitors to radiosensitize liver tumours

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Attributable risks

Chairs: **Isabelle Soerjomataram**, IARC, Lyon, France & **Max Parkin**, University of Oxford, United Kingdom

Speakers:

1. **Farhad Islami (USA):** The proportion of cancer attributable to major modifiable lifestyle and environmental factors in China, 2011
2. **Kevin Shield (IARC):** The global burden of cancer in 2012 attributable to alcohol
3. **Anabelle Gilg Soit Ilg (France):** Estimates of the fraction of several cancers attributable to occupational exposure to certain carcinogens in France
4. **Leandro Rezende (Brazil):** Burden of cancer attributable to physical inactivity in Brazil
5. **Martyn Plummer (IARC):** Global burden of cancer attributable to infections

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Thursday 9 June 2016 - 14:30 – 15:30

Wednesday 8 June 2016

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Occupation

Chairs: **Dana Loomis**, IARC, Lyon, France & **Jack Siemiatycki**, Université de Montréal, Canada

Invited Speaker: **Jack Siemiatycki**, Université de Montréal, Canada

"Occupation and cancer"

Speakers:

1. **Laura Beane Freeman (USA):** Pesticide use and cancer incidence among spouses of pesticide applicators in the Agricultural Health Study
2. **Ann Olsson (IARC):** Exposure-response analyses of asbestos and lung cancer subtypes in a pooled analysis of case-control studies in Europe and Canada
3. **Lidija Latifovic (Canada):** Bladder cancer and occupational exposure to diesel and gasoline engine emissions among Canadian men

MECHANISMS in Tête d'Or Room (level 1)

Theme: Genetics and (epi)genomics

Chairs: **Zdenko Herceg**, IARC, Lyon, France & **David Goldgar**, University of Utah, Salt Lake City, USA

Speakers:

1. **Rayjean Hung (Canada):** Cross-cancer genome-wide pleiotropy analysis based on GAME-ON and GECCO across five common cancers: lung, ovary, breast, prostate and colon cancers
2. **David Goldgar (USA):** The value of large international consortia in characterizing genetic susceptibility to breast cancer
3. **Corina Lesseur (IARC):** Genome-wide study of head and neck cancer
4. **Florence Guida (United Kingdom):** Epigenetic markers of smoking-induced lung cancer: screening and risk
5. **Akram Ghantous (IARC):** Identifying epigenetic precursors of childhood cancer and associated early-life exposure factors

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Infection control to prevent cancer

Chairs: **Silvia Franceschi**, IARC, Lyon, France & **Aimée Kreimer**, United States National Cancer Institute, Bethesda, USA

Speakers:

1. **Gary Clifford (IARC):** Monitoring HPV vaccination program impact in Bhutan and Rwanda
2. **Jerry Polesel (Italy):** The impact of HBV vaccination on B-cell non-Hodgkin lymphoma
3. **Qian Zhang (China):** Expression of E6 oncoprotein and incidence of high cervical precancerous lesions among HPV-infected women: 5-year follow-up results in a Chinese cohort
4. **Sumantra Ghosh (France):** High incidence of a hepatitis B virus preS2 deletion in West Africa among HBV chronic carriers: association with hepatocellular carcinoma
5. **Silvia de Sanjosé (Spain):** HPV burden in HPV-related lesions

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Thursday 9 June 2016 - 16:00 – 17:00

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Radiation

Chairs: **Ausrele Kesminiene**, IARC, Lyon, France & **Shunichi Yamashita**, Nagasaki University and Fukushima Medical University, Nagasaki, Japan

Invited Speaker: **Shunichi Yamashita**, Nagasaki University and Fukushima Medical University, Nagasaki, Japan
“Radiation and health effects: a gap between understanding of real radiation health risk and public risk perception, beyond the accumulated scientific knowledge”

Speakers:

1. **Amy Berrington (USA):** New results from the UK-NCI Pediatric CT scans study
2. **Garthika Navaranjan (Canada):** Radon exposure and cancers other than lung among Ontario uranium miners
3. **Ghiasvand Reza (Norway):** Age at first indoor tanning use and melanoma risk: a prospective, population-based cohort study

MECHANISMS in Tête d'Or Room (level 1)

Theme: Bioinformatics

Chairs: **James McKay**, IARC, Lyon, France & **Roland Eils**, German Cancer Research Center (DKFZ), Heidelberg, Germany

Invited Speaker: **Roland Eils**, German Cancer Research Center (DKFZ), Heidelberg, Germany
“Big data in cancer: curse or cure”

Speakers:

1. **Maude Ardin (IARC):** Comprehensive analysis of A:T>T:A mutational signatures in human cancers
2. **Kaitlin Wade (United Kingdom):** MR-Base: an online platform for Mendelian randomization using summary data
3. **Neela Guha (IARC):** Prioritizing chemicals for risk assessment using chemoinformatics: examples from the IARC Monographs on pesticides

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Survival, survivorship and inequalities

Chairs: **Valerie McCormack**, IARC, Lyon, France & **Giske Ursin**, Cancer Registry of Norway, Oslo, Norway

Speakers:

1. **Diana Withrow (Canada):** Disparities in cancer survival between indigenous and non-indigenous adults in Canada: results from linkage of the 1991 Census Mortality Cohort and the Canadian Cancer Registry
2. **Fiona McKenzie (IARC):** Determinants of late-stage breast cancer diagnosis in the multi-country African Breast Cancer – Disparities in Outcomes (ABC-DO) Study
3. **Anna Gavin (United Kingdom):** Effect of prostate cancer investigation and treatment intensity on reported long-term physical condition and health-related quality of life: a two-country study
4. **Hanna Tervonen (Australia):** Cancer survival disparities in New South Wales, Australia over 30 years
5. **Luis Felipe Ribeiro Pinto (Brazil):** Factors associated with survival in individuals diagnosed with head and neck cancer in a public institution of reference in Rio de Janeiro, Brazil

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Thursday 9 June 2016

Wednesday 8 June 2016



Stephen Chanock

Director of the Division of Cancer Epidemiology and Genetics, United States National Cancer Institute, Bethesda, USA

Dr Stephen Chanock is a leading expert in the discovery and characterization of cancer susceptibility regions in the human genome. He has received numerous awards for his scientific contributions to our understanding of common inherited genetic variants associated with cancer risk and outcomes. Dr Chanock received his MD from Harvard Medical School in 1983 and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology and research training in molecular genetics at Boston Children's Hospital and the Dana-Farber Cancer Institute, Boston. Since 1995, Dr Chanock has served as the Medical Director for Camp Fantastic, a week-long recreational camp for pediatric cancer patients, which is a joint venture of the NCI and Special Love, Inc. From 2001 to 2007, he was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in the NCI Center for Cancer Research. He also served as Co-Chair of NCI's Genetics, Genomics and Proteomics Faculty for five years. In 2001, he was appointed as Chief of the Cancer Genomics Research Laboratory (formerly Core Genotyping Facility), and in 2007 as Chief of the Laboratory of Translational Genomics, both within the NCI Division of Cancer Epidemiology and Genetics (DCEG). Dr Chanock co-led the Cancer Genetic Markers of Susceptibility project. From 2012 to 2013, he also served as Acting Co-Director of the NCI Center for Cancer Genomics. Dr Chanock was appointed Director of DCEG in August 2013.

Plenary session: "Germline mutations"

Room: Amphithéâtre 3000 / 9:00 – 9:30



Valerie Beral

Director, Cancer Epidemiology Unit, University of Oxford, United Kingdom

Born in Australia, Dame Valerie studied medicine at Sydney University, graduating in 1969. As the top graduate that year she was awarded the University Gold Medal, the first woman ever to receive this award in medicine. She worked for one of the first clinical epidemiologists in the United Kingdom, Charles Fletcher, who propelled her towards the London School of Hygiene and Tropical Medicine, where she worked for almost 20 years. In 1988 she became Director of the University of Oxford Cancer Epidemiology Unit, previously directed by Sir Richard Doll. Her major research interests include the role of reproductive, hormonal and infectious agents in cancer and other conditions. She is Principal Investigator of the Million Women Study, investigating the effects of a range of women's lifestyle factors on health, with focus initially on the effects of hormone replacement therapy. Since 1991, she has led international collaborative studies of breast, ovarian and endometrial cancers. She has served on many international committees, including the World Health Organization, the United States National Academy of Sciences, and various Australian cancer councils. Until recently, she chaired the United Kingdom Department of Health's Advisory Committee on Breast Cancer Screening and is currently a member of the Board of the Medicines and Healthcare Products Regulatory Agency. In 2006 she was elected Fellow of the Royal Society (FRS) for scientific contributions to epidemiology. Other honours include being invested as Dame of the British Empire (DBE) and Companion of Australia.

Plenary session: "The impact of tobacco, alcohol and hormones on women's cancers"

Room: Amphithéâtre 3000 / 9:30 – 10:00



Lynette Denny, Recipient of 2016 IARC Medal of Honour

Chair and Professor of Obstetrics & Gynaecology and registered sub-specialist in Gynaecological Oncology at Groote Schuur Hospital and University of Cape Town, South Africa

Lynette Denny is the Chair and Professor of Obstetrics & Gynaecology and registered sub-specialist in Gynaecological Oncology at Groote Schuur Hospital and the University of Cape Town. Her research interest for the past 15 years has been in preventing cervical cancer in low-resource settings, and she has published over 100 peer-reviewed papers on the subject. She has been a keynote speaker at numerous international conferences. She was awarded the Distinguished Scientist for Improving the Quality of Life of Women by the South African Department of Science and Technology in 2006 and is a B2 rated scientist by the National Research Foundation of South Africa. She was the first recipient of the Shoprite Checkers SABC 2 Women of the Year award for Science and Technology in 2004. She was awarded the South African Medical Association award for Extraordinary Service to Medicine (2012) and given a fellowship ad eundem to the Royal College of Obstetrics and Gynaecology, United Kingdom (2012). Professor Denny was presented with the BSCCP Founders' Medal at the 15th World Congress for Cervical Pathology and Colposcopy in London, United Kingdom in May 2014. This award is in recognition of the outstanding contribution she has made to women's health and the prevention of cervical cancer in Africa. In October 2015 Professor Denny was presented with the International Federation of Gynecology and Obstetrics (FIGO) Award in Vancouver, Canada. This award is in recognition of women obstetricians and gynaecologists.

Plenary session: "Screening and early detection of cervical cancer in Africa"

Room: Amphithéâtre 3000 / 10:00 – 10:30

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Thursday 9 June 2016



Armando Peruga

Programme manager of Tobacco Free Initiative, World Health Organization, Geneva, Switzerland

Dr Peruga began to work with the Pan American Health Organization in 1990. He was the leader of the tobacco control team of this organization until the beginning of 2006, when he moved to Geneva as the Coordinator for the capacity building unit of the Tobacco Free Initiative of the World Health Organization. In Spain, he was the Director of the Research Institute on Health and Welfare in Madrid. He later became the Dean of the National School of Public Health. When he went to the USA in the early 1980s, he worked for the DC Commission of Public Health as a behavioral change epidemiologist. Dr Peruga graduated in Medicine in Spain. He later graduated from Master's and Doctoral programs of the Johns Hopkins Bloomberg School of Public Health.



Jean-François Etter

Professor, Faculty of Medicine, University of Geneva, Switzerland

Jean-François Etter has been conducting research on smoking etiology, prevention and cessation for over 20 years. He has published widely on smoking cessation trials and various psychological questions related to tobacco dependence and smoking cessation. He is an internationally known expert on e-cigarettes. He has published a comprehensive book on e-cigarettes and is credited with publishing some of the first scientific papers on the reasons and patterns of e-cigarette use. Professor Etter's basic training was in political science and public health. He is a Professor in the Faculty of Medicine of the University of Geneva, Switzerland.

Panel debate: "E-cigarettes represent a barrier to effective tobacco control"

Room: Amphithéâtre 3000 / 12:10 – 12:55



Michael Marmot

Director, University College London Institute of Health Equity (Marmot Institute), United Kingdom

Sir Michael Marmot has led research groups on health inequalities for more than 35 years. He chaired the Commission on Social Determinants of Health, set up by WHO in 2005, and produced the report *Closing the Gap in a Generation* in 2008. He conducted a Strategic Review of Health Inequalities in England Post-2010, which published the report *Fair Society, Healthy Lives* in 2010. He chaired the European Review of Social Determinants of Health and the Health Divide, for the WHO European Regional Office, and the Breast Screening Review for the NHS National Cancer Action Team, and was a member of The Lancet-University of Oslo Commission on Global Governance for Health. He is a Principal Investigator of the Whitehall II studies of health inequalities among British civil servants, and leads the English Longitudinal Study of Ageing. He is a former President of the British Medical Association and the current President of the British Lung Foundation. He was a member of the Royal Commission on Environmental Pollution for six years, and in 2000 was knighted by the Queen, for services to epidemiology and the understanding of health inequalities. He won the Balzan Prize for Epidemiology in 2004, gave the Harveian Oration in 2006, and won the William B. Graham Prize for Health Services Research in 2008. He was awarded a Harvard Lown Professorship for 2014–2017. He is President of the World Medical Association since 2015. He has been awarded honorary doctorates from 14 universities.

Plenary session: "Reducing inequalities in risk"

Room: Amphithéâtre 3000 / 17:10 – 17:40



Graham Colditz

Deputy Director, Institute for Public Health; Chief, Division of Public Health Sciences; Niess-Gain Professor of Surgery, School of Medicine; and Associate Director, Prevention & Control, Siteman Cancer Center, Washington University in St. Louis, USA

Dr Colditz is an internationally recognized leader in cancer prevention. As an epidemiologist and public health expert, he has a longstanding interest in the preventable causes of chronic disease, particularly among women. He focuses his research on early life and adolescent lifestyle, growth, and breast cancer risk. He is also interested in strategies to speed translation of research findings into prevention strategies that work. Dr Colditz developed the award-winning Your Disease Risk website (www.yourdiseaserisk.wustl.edu), which communicates tailored prevention messages to the public. He has published over 975 peer-reviewed publications, six books and six reports for the Institute of Medicine, National Academy of Sciences. In October 2006, on the basis of professional achievement and commitment to public health, Dr Colditz was elected to membership of the Institute of Medicine, an independent body that advises the United States government on issues affecting public health. In 2011, he was awarded the American Cancer Society Medal of Honor for cancer control research. In 2012 he received the AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention. He also received awards in 2014 for cancer prevention research from ASCO and from AACR.

Plenary session: "Implementing strategies to prevent cancer"

Room: Amphithéâtre 3000 / 17:40 – 18:10

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Thursday 9 June 2016

Wednesday 8 June 2016



Christine Friedenreich

Cancer epidemiologist, Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services. Adjunct Professor, Faculties of Medicine and Kinesiology, University of Calgary, Canada

Dr Friedenreich is a cancer epidemiologist with the Department of Cancer Epidemiology and Prevention Research (CEPR) of CancerControl Alberta, Alberta Health Services and an Adjunct Professor in the Faculties of Medicine and Kinesiology of the University of Calgary. She holds a Health Senior Scholar career award from Alberta Innovates-Health Solutions and in 2012 was named the Alberta Cancer Foundation's Weekend to End Women's Cancers Breast Cancer Chair at the University of Calgary. Dr Friedenreich is the Scientific Director for CEPR and the Division Head for the Division of Preventive Oncology, Department of Oncology, Faculty of Medicine, University of Calgary. Dr Friedenreich completed her doctorate in Epidemiology at the University of Toronto in 1990 and postdoctoral work at the International Agency for Research on Cancer (IARC) in Lyon, France and at the University of Calgary between 1990 and 1994. In 2004–2005, Dr Friedenreich was a Visiting Scientist at IARC. In 2013, Dr Friedenreich was a co-recipient of the Canadian Cancer Society's O. Harold Warwick Prize. Dr Friedenreich's research is focused on understanding the role of physical activity in reducing the risk of developing cancer and in improving quality of life and survival after cancer diagnosis. She has conducted over 35 observational epidemiologic and randomized controlled intervention trials in this area.

Parallel session: "Nutrition, obesity and exercise"

Room: Amphithéâtre 3000 / 11:00 – 12:00



Michael Leitzmann

Chair of the Department of Epidemiology and Preventive Medicine, University of Regensburg, Germany

Michael Leitzmann received an MD from the University of Berlin and completed an MPH and a DrPH at the Harvard School of Public Health. He subsequently joined the Division of Cancer Epidemiology and Genetics of the United States National Cancer Institute as investigator. In 2008, he was appointed Professor and Chair of the Department of Epidemiology and Preventive Medicine at the University of Regensburg, Germany. He leads an interdisciplinary team of scientists on research related to epidemiology, biostatistics, bioinformatics, nutritional health, and sociology. A major focus is the relationship between energy balance and cancer. This includes investigations of the independent and joint relations of body mass, physical activity, sedentary behavior, and diet in relation to cancer incidence and survival. The energy balance research is characterized by the development and application of methods to validly measure body composition and energy expenditure in large population-based cohorts. Professor Leitzmann has published more than 200 research articles, serves as editorial board member and reviewer to numerous biomedical journals, and acts as scientific consultant to several national and international advisory boards and research institutions. He is a member of the International Epidemiological Association, the American College of Epidemiology, and the Society for Epidemiologic Research.

Parallel session: "Nutrition, obesity and exercise"

Room: Amphithéâtre 3000 / 11:00 – 12:00



Hitoshi Nakagama

President, National Cancer Center (NCC), Tokyo, Japan

Hitoshi Nakagama graduated from the University of Tokyo in 1982 and received his MD from the University of Tokyo in 1991. He then moved to the USA and joined the Center for Cancer Research, MIT, and worked as a postdoctoral fellow on the functional analysis of the tumour suppressor gene, WT1, with Professor David Housman. After returning to Japan in 1995, he took up a position as Section Head, Carcinogenesis Division, National Cancer Center Research Institute (NCCRI), and then became Chief, Biochemistry Division (1997), Deputy Director (2007), and Director of NCCRI in 2011. From April 1, 2016, he now serves as President of the National Cancer Center. He has long been working on animal cancer models of colon carcinogenesis induced by various environmental carcinogens and on the DNA adductome to elucidate genetic and epigenetic modifications which play pivotal roles in driving cancer development. He also identified several tumour suppressive microRNAs regulating cell cycle arrest and/or apoptosis after exposure to environmental damage, and proved that these tumour suppressive microRNAs are inactivated during colon carcinogenesis, including in the phase of liver metastasis. He is currently working on the application of exosomal microRNA in the early detection of various cancers.

Parallel session: "DNA damage, repair and mutagenesis"

Room: Tête d'Or (level 1) / 11:00 – 12:00

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Thursday 9 June 2016



Jack Siemiatycki

Professor of epidemiology, Université de Montréal, Canada

Jack Siemiatycki has a PhD in epidemiology and is currently Professor of epidemiology at Université de Montréal. He has held a Canada Research Chair and is currently the Guzzo-SRC Chair in Environment and Cancer, and is a Fellow of the Canadian Academy of Health Sciences. He has served on over 100 national and international boards and expert advisory bodies for academic and government agencies in Canada, the USA and Europe, such as the National Cancer Institute of Canada, the Canadian Institutes of Health Research, the National Cancer Institute (USA), the Institut de Recherche en Santé publique (France), INSERM (France), the American College of Epidemiology, IARC and WHO. He has served on the editorial board of the *American Journal of Epidemiology* and other journals, and has chaired many grant review panels. Most of his research has been in the area of environmental and occupational etiology of cancer. He is known for having developed novel and influential design and exposure assessment methods in the occupational etiology of cancer, and for results from a variety of case-control studies concerning a wide variety of possible environmental carcinogens. Professor Siemiatycki has been an invited speaker at over 150 meetings or seminars throughout the world, including for President Clinton's Cancer Panel, and as a Distinguished Lecturer at the United States National Cancer Institute. He has authored or co-authored over 200 peer-reviewed articles, 50 scientific reports, and 150 invited presentations or posters. He was the principal expert witness in the largest ever successful class action lawsuit against the tobacco industry.

Parallel session: "Occupation"

Room: Amphithéâtre 3000 / 14:30 – 15:30



Shunichi Yamashita

Trustee and Vice-President, Nagasaki University and part-time Vice-President, Fukushima Medical University, Japan

Shunichi Yamashita graduated from the Nagasaki University School of Medicine in March 1978 and spent almost three years from July 1984 to March 1987 as the first endocrine research fellow at the Cedars-Sinai Medical Center, Los Angeles. In October 1990, Dr Yamashita became Professor of Molecular Medicine and International Radiation Health at the Atomic Bomb Disease Institute, Nagasaki University School of Medicine. He has been deeply involved in Chernobyl and Semipalatinsk medical aid and research projects for 25 years. Professor Yamashita is the Adviser to the Governor of Fukushima Prefecture on Health Risk Management immediately after the Fukushima Nuclear Power Plant (NPP) accident. He was dispatched from Nagasaki University to Fukushima for two years after the Fukushima NPP accident. Since April 2013, he has been mainly in Nagasaki University but partly in Fukushima Medical University. He is still in charge of the Fukushima Health Management Survey, especially for the thyroid examination as a part-time Vice-President of Fukushima Medical University. Professor Yamashita is the Director of the WHO collaborating centre for research on Radiation Emergency Medical Preparedness and Response Network, council member of the Science Council of Japan and a member of the Nuclear Disaster Expert Group of the Prime Minister's Office in Japan. He is the former President of the Japan Thyroid Association.

Parallel session: "Radiation"

Room: Amphithéâtre 3000 / 16:00 – 17:00



Roland Eils

German Cancer Research Center (DKFZ), Heidelberg, Germany

Roland Eils received his PhD in Mathematics from the University of Heidelberg, Germany, in 1995. He is currently a Professor at the University of Heidelberg and holds a joint appointment as division head at the German Cancer Research Center (DKFZ) in Heidelberg. He is founding and managing Director of BioQuant, the Center for Quantitative Analysis of Molecular and Cellular Biosystems at the University of Heidelberg. His research focuses on the integration of tools from mathematical modeling, image analysis and informatics into life science research and he is a leading figure in systems biology and bioinformatics. In his research, he is applying various methods on issues related to human health, such as viral infection, cellular death pathways and cancer genomics. He has published more than 280 papers in peer-reviewed journals over the past 10 years and received a total of more than 10 000 citations from them. He is co-editor of the book *Computational Systems Biology* (Elsevier) and is the Editor-in-Chief of *systembiologie.de*, the magazine for systems biology research in Germany. Professor Eils is coordinating the several systems biology and systems medicine consortia and is the coordinator of HD-HuB, the Heidelberg Center for Human Bioinformatics. He is a member of the International Society for Systems Biology (ISSB). In 1999 he was awarded the BioFuture Prize, the most prestigious prize for young researchers in Germany, and in 2014 he received the Heidelberg Molecular Life Sciences (HMLS) Investigator Award.

Parallel session: "Bioinformatics"

Room: Tête d'Or (level 1) / 16:00 – 17:00

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Plenary Sessions

Friday 10 June 2016 - Amphithéâtre 3000

Wednesday 8 June 2016

Chairs: **Marc Gunter**, IARC, Lyon, France & **Giota Mitrou**, World Cancer Research Fund International, London, United Kingdom

9:00 – 9:30	Walter Willett , Harvard T.H. Chan School of Public Health, Boston, USA The American Institute for Cancer Research and World Cancer Research Fund International Lecture Diet, weight control and energy balance in cancer
-------------	---

Chairs: **Rolando Herrero**, IARC, Lyon, France & **Bernard W. Stewart**, South Eastern Sydney Public Health Unit, Australia

9:30 – 10:00	George Davey Smith , University of Bristol, United Kingdom Causality and chance in the origins of cancer
--------------	--

10:00 – 10:30	Flora van Leeuwen , Netherlands Cancer Institute, Amsterdam, Netherlands Risk factors for second cancers
---------------	--

10:30 – 11:00	Coffee break - Level –2
---------------	--------------------------------

11:00 – 12:00	Parallel Sessions (details on page 29)
---------------	---

Chair: **Sam Hanash**, MD Anderson Cancer Center, Houston, USA

12:10 – 12:55	Panel Debate 3 Screening for lung cancer should be implemented now Pro: John Field , University of Liverpool Cancer Research Centre, United Kingdom Anti: Harry J. de Koning , Erasmus Medical Center, Rotterdam, Netherlands
---------------	--

12:55 – 14:00	Lunch break and Poster session - Level –2
---------------	--

Chairs: **David Forman**, IARC, Lyon, France & **Elisabete Weiderpass**, Karolinska Institute, Stockholm, Sweden

14:00 – 15:00	PROFFERED PAPERS PLENARY SESSION
	1. Ling Yang (China) : Parity, age at first birth, breastfeeding and breast cancer risk: a nationwide prospective study of 300 000 Chinese women
	2. Ausrele Kesminiene (IARC) : Risk of cancer mortality from occupational exposure to ionizing radiation: results of the International Cohort Study of Radiation Workers (INWORKS)
	3. Loïc Le Marchand (USA) : Ethnic/racial differences in visceral and liver fat distributions in the multi-ethnic cohort
	4. Stephen Hecht (USA) : Mechanisms of ethnic/racial differences in lung cancer susceptibility evaluated with tobacco smoke toxicant and carcinogen biomarkers and genetic studies
	5. Rafaela Naves (Brazil) : Socioeconomic status and delays in diagnosis and treatment: are there influences on childhood cancer survival in São Paulo, Brazil?
	6. Willie Yu (Singapore) : Genome-wide AFB1-induced mutational signature in cells, mice and human tumours – implications for molecular epidemiology

Chairs: **Christopher P. Wild**, IARC, Lyon, France & **Paul Kleihues**, University of Zurich, Switzerland

15:00 – 15:30	Elio Riboli , Imperial College London, United Kingdom Consortia, big data and the future of population research
---------------	---

15:30 – 16:00	Richard Peto , University of Oxford, United Kingdom Successes in understanding the causes of cancer
---------------	---

16:00 – 16:30	Closing of Conference
---------------	------------------------------

Thursday 9 June 2016

Friday 10 June 2016

Parallel Sessions

Friday 10 June 2016 - 11:00 – 12:00

EPIDEMIOLOGY in Amphithéâtre 3000

Theme: Environmental exposures

Chairs: **Ann Olsson**, IARC, Lyon, France & **Manolis Kogevinas**, Centre for Research in Environmental Epidemiology, Barcelona, Spain

Invited Speaker: **Manolis Kogevinas**, Centre for Research in Environmental Epidemiology, Barcelona, Spain
"Environment and cancer"

Speakers:

1. **Manisha Pahwa (Canada):** A detailed assessment of glyphosate use and the risks of non-Hodgkin lymphoma overall and by major histological sub-types: findings from the North American Pooled Project
2. **Dana Hashim (USA):** The role of oral hygiene in head and neck cancer: results from the International Head and Neck Cancer Epidemiology (INHANCE) Consortium
3. **Michelle Plusquin (United Kingdom):** Exposure to ambient air pollution and global DNA methylation

MECHANISMS in Tête d'Or Room (level 1)

Theme: Metabolomics and biomarkers

Chairs: **Augustin Scalbert**, IARC, Lyon, France & **Nathaniel Rothman**, United States National Cancer Institute, Bethesda, USA

Speakers:

1. **Nathaniel Rothman (USA):** High-resolution metabolomics of occupational exposure to trichloroethylene
2. **Marion Carayol (IARC):** Associations between body mass index, physical activity and 145 blood metabolites: a targeted metabolomic approach in the EPIC cohort
3. **Demetrius Albanes (USA):** Serum metabolomic profiling of prostate cancer risk in the PLCO cancer screening trial
4. **Eline van Roekel (Netherlands):** A metabolome-wide association study of alcohol consumption and smoking in the EPIC cohort
5. **Karl Smith Byrne (United Kingdom):** A nested case-control study of plasma microseminoprotein-beta and prostate cancer risk in the EPIC cohort

PREVENTION & MORTALITY REDUCTION in Gratte-Ciel Room (level 2)

Theme: Implementation research

Chairs: **Raúl Murillo**, IARC, Lyon, France & **Suzanne Heurtin-Roberts**, United States National Cancer Institute, Bethesda, USA

Invited Speaker: **Mauricio Maza**, Basic Health International, San Salvador, El Salvador
"How research can lead to implementation in limited-resource settings: the case of El Salvador"

Speakers:

1. **Sujha Subramanian (USA):** Clinical trial to implementation in India: cost and effectiveness considerations for scaling up cervical cancer screening in low- and middle-income countries
2. **Anne Cust (Australia):** Evaluation of the feasibility and acceptability of giving information on personalized genomic risk of melanoma to the public, and its impact on sun protection and skin examination behaviours, psycho-social and ethical issues
3. **Silvina Arrossi (Argentina):** Implementation research to evaluate scaling-up of HPV self-collection in the Province of Jujuy, Argentina

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Friday 10 June 2016

Wednesday 8 June 2016



Walter Willett

Professor of Epidemiology and Nutrition and Chairman of the Department of Nutrition at the Harvard T.H. Chan School of Public Health and Professor of Medicine at Harvard Medical School, Boston, USA

Dr Walter Willett is Professor of Epidemiology and Nutrition and Chairman of the Department of Nutrition at the Harvard T.H. Chan School of Public Health and Professor of Medicine at Harvard Medical School. Dr Willett studied food science at Michigan State University, and graduated from the University of Michigan Medical School before obtaining a Doctorate in Public Health from the Harvard School of Public Health. Dr Willett has focused much of his work over the last 35 years on the development of methods, using both questionnaire and biochemical approaches, to study the effects of diet on the occurrence of major diseases. He has applied these methods starting in 1980 in the Nurses' Health Studies I and II and the Health Professionals Follow-up Study. Together, these cohorts that include nearly 300 000 men and women with repeated dietary assessments are providing the most detailed information on the long-term health consequences of food choices. Dr Willett has published over 1500 articles, primarily on lifestyle risk factors for heart disease and cancer. Dr Willett is the most cited nutritionist internationally, and is among the five most cited persons in all fields of clinical science. He is a member of the Institute of Medicine of the National Academy of Sciences and the recipient of many national and international awards for his research.

Plenary session: "Diet, weight control and energy balance in cancer"

Room: Amphithéâtre 3000 / 9:00 – 9:30



George Davey Smith

Professor of Clinical Epidemiology, University of Bristol; Honorary Professor of Public Health, University of Glasgow; Visiting Professor, The London School of Hygiene and Tropical Medicine, United Kingdom

George Davey Smith is Professor of Clinical Epidemiology at the University of Bristol, Honorary Professor of Public Health at the University of Glasgow and Visiting Professor at the London School of Hygiene and Tropical Medicine. He is Scientific Director of the Avon Longitudinal Study of Parents and Children and Director of the Medical Research Council's Integrative Epidemiology Unit. His major research interests relate to the use of genetic epidemiology for informing understanding of the causal influence of environmentally modifiable risk factors and how social inequalities in health are generated by exposures acting over the entire lifecourse. Professor Smith has also worked on HIV/AIDS prevention in Nicaragua and India and on issues around the history of epidemiology, meta-analysis, lay epidemiology and epidemiological methodology. He is co-editor of the *International Journal of Epidemiology*.

Plenary session: "Causality and chance in the origins of cancer"

Room: Amphithéâtre 3000 / 9:30 – 10:00



Flora van Leeuwen

Head of the Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands

Flora E. van Leeuwen graduated from the Wageningen Agricultural University (MSc in Human Nutrition) in 1981 (cum laude). In the same year she became Head of the Department of Tumor Documentation, Clinical Trials and Epidemiology of the Netherlands Cancer Institute in Amsterdam, with the specific task to start an Epidemiology Group in that institute. In 1982–1983, she was awarded a research training fellowship by the International Agency for Research on Cancer and obtained an MSc degree in Epidemiology from the Department of Epidemiology of the School of Public Health of the University of Alabama in Birmingham, USA. From 1986 to 2010, she was Head of the Epidemiology Group of the Netherlands Cancer Institute. From 2010 onwards, she has been heading the Division of Psychosocial Research and Epidemiology in the Netherlands Cancer Institute. Her research group currently focuses on two main research lines: (i) the assessment of the long-term risks of second malignancy, cardiovascular disease and other comorbidities following treatment for Hodgkin's lymphoma, breast cancer, testicular cancer and childhood malignancy; the development and evaluation of cancer survivorship care programs and (ii) the assessment of the roles of hormone-related and genetic risk factors in the etiology of breast and ovarian cancers; special interest is in late effects of ovarian stimulation for in vitro fertilization and cancer etiology in BRCA1/2 families. In 1998 Flora van Leeuwen obtained a Chair in Cancer Epidemiology at The Faculty of Medicine from the Vrije Universiteit in Amsterdam.

Plenary session: "Risk factors for second cancers"

Room: Amphithéâtre 3000 / 10:00 – 10:30

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Friday 10 June 2016



John Field

Director of Research, Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, United Kingdom

Professor John Field has a Personal Clinical Chair in Molecular Oncology at the University of Liverpool. He is a Visiting Professor at University College London and holds the post of Director of Research of the Roy Castle Lung Cancer Research Programme. He is the Chief Investigator for the UK Lung Cancer Screening Trial and Chair of the European Union-United States Spiral CT Collaborative Group (2011–). He was the previous Chair of the International Association for the Study of Lung Cancer (IASLC) Screening Prevention & Early Detection Committee and he formed the IASLC Strategic Screening Advisory Group, which he chairs. He was presented with the IASLC Joseph Cullen Award at the World Conference on Lung Cancer in 2011, in recognition of his lifetime scientific achievements in lung cancer prevention research. He is the Principal Investigator of the Liverpool Lung Project, a molecular-epidemiological study into the early detection of lung cancer, funded by the Roy Castle Lung Cancer Foundation. He is also PI on the large EU Early Lung Cancer study funded by the European Commission. Both of these trials form part of the National Cancer Research Institute Lung Cancer Clinical studies group's portfolio. A Partner in the FP7 CURELUNG and Lung Cancer Artificial Olfactory System projects, he is also heavily involved in the identification of molecular diagnostic markers in lung and head and neck cancers. His research funding has been provided mainly by the Rarer Cancers Foundation, North West Cancer Research Fund, the Medical Research Council, Cancer Research UK, the European Union, the National Institutes of Health and Health Technology Assessment.



Harry J. de Koning

Professor of Public Health & Screening Evaluation, Department of Public Health, Erasmus Medical Center, Rotterdam, Netherlands

Born in the Netherlands, Professor Henricus (Harry) J. de Koning worked as a Researcher and an Assistant Professor in the department of Public Health of the Erasmus University in Rotterdam from 1987 to 1999. He became an Associate Professor in 1999, and in 2008 he was appointed Professor of Public Health & Screening Evaluation in the same department in Rotterdam. He was also Senior Associate in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health from 2011 to 2012. Since 2011, he has been a Member of the Medical Advisory Board of the Royal Netherlands Academy of Arts and Sciences (KNAW). His major scientific contributions are in the areas of: designing, running and evaluating large-scale multidisciplinary population-based randomized controlled screening trials to establish the efficacy of screening, evaluating active international screening programmes and tests to establish effectiveness, guiding public health policies using predictions of favourable and unfavourable effects and the cost of screening, based on micro-simulation modeling of the natural history of disease, and cost-effectiveness and cost-utility analyses.

Panel debate: "Screening for lung cancer should be implemented now"

Room: Amphithéâtre 3000 / 12:10 – 12:55



Elio Riboli

Director, School of Public Health, Imperial College London, United Kingdom

Professor Elio Riboli's career started at the Department of Epidemiology of the National Institute of Cancer, Milan (1978–1983). In 1983 Dr Riboli was appointed Medical Officer in Epidemiology at the International Agency for Research on Cancer (IARC). While at IARC he engaged in a novel area of research focusing on the role of diet, nutrition and endogenous hormones in cancer etiology. In 1990 this materialized into the initiation of the European Prospective Investigation into Cancer and Nutrition (EPIC), and its subsequent funding by the "Europe Against Cancer" programme of the European Commission, from 1992 onward. Over the past decade, Dr Riboli has led research contributing to the discovery of the role of metabolic factors (obesity, insulin resistance and other components of the so-called "metabolic syndrome") in cancer causation. These results have translated into worldwide public health guidance by international bodies such as the World Health Organization and the World Cancer Research Fund. While working at IARC, during the period 1990–2005, he received joint appointments as Adjunct Professor in the Department of Environmental Medicine at New York University and as Senior Visiting Scientist at the National Cancer Institute, National Institutes of Health, in the USA. In 2006 Dr Riboli was appointed Professor and Chair in Cancer Epidemiology and Prevention and, in 2008, Director of the School of Public Health, Imperial College London. He is also Chair of the Interventional Public Health Clinical Programme Group of the Imperial College Academic Health Science Centre (AHSC) and Director of Research in Public Health of the Imperial College National Health Service Healthcare Trust, providing a direct link between academic research, public health and clinical translation.

Plenary session: "Consortia, big data and the future of population research"

Room: Amphithéâtre 3000 / 15:00 – 15:30

Wednesday 8 June 2016

Thursday 9 June 2016

Friday 10 June 2016

Invited Speakers

Friday 10 June 2016

Wednesday 8 June 2016



Richard Peto

Professor of Medical Statistics and Epidemiology and co-Director of the Clinical Trial Service Unit, University of Oxford, United Kingdom

Richard Peto is a Professor of Medical Statistics and Epidemiology and a co-Director of the Clinical Trial Service Unit at the University of Oxford. He studied natural sciences at Cambridge University and obtained his MSc in statistics at the University of London. Professor Peto's work has included studies of the causes of cancer in general, and of the effects of smoking in particular, and the establishment of large-scale randomized trials of the treatment of cancer and various other diseases. He has been instrumental in introducing combined "meta-analyses" of results from diverse studies. Dr Peto is one of the world's most cited medical researchers, and he was knighted in 1999 for his services to epidemiology and cancer prevention. He devotes much of his energy to advising and providing information on "avoidable death". His work continues to have a direct influence on public policy and adult mortality in many countries.

Plenary session: "Successes in understanding the causes of cancer"

Room: Amphithéâtre 3000 / 15:30 – 16:00



Manolis Kogevinas

Co-Director, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

Professor Manolis Kogevinas is co-Director of the Centre for Research in Environmental Epidemiology (CREAL). He graduated from the Medical School of Athens, Greece and did his PhD in Epidemiology at the University of London (1989). He worked at the International Agency for Research on Cancer (IARC), Lyon, at the Municipal Institute of Medical Research (IMIM) in Barcelona and was Professor of Epidemiology at the Medical School in Heraklion, Crete and at the National School of Public Health in Athens. His major research interest relates to the evaluation of environmental and occupational exposures in relation to cancer, respiratory diseases and child health. He served on several WHO and other expert committees evaluating the toxicity of chemicals such as dioxins and drinking-water contaminants. He is the Director of the European Educational Programme in Epidemiology (EEPE-Florence course). He is President (2016–2017) of the International Society for Environmental Epidemiology (ISEE).

Parallel session: "Environmental exposures"

Room: Amphithéâtre 3000 / 11:00 – 12:00



Mauricio Maza

Chief Medical Officer, Basic Health International, San Salvador, El Salvador

Dr Mauricio Maza is the Chief Medical Officer for Basic Health International, an organization dedicated to the eradication of cervical cancer. He received his MD from the Universidad Dr José Matías Delgado in El Salvador, and his Master's of Public Health from Harvard University with a concentration in Health Care Management and Policy. As a medical doctor, public health practitioner and researcher, Dr Maza's focus is cervical cancer prevention in low-resource settings, specifically with the use of novel technologies and treatment paradigms. He is a co-investigator in NIH-funded studies that include development of technologies for screening, triaging and treatment of pre-cancerous lesions. Dr Maza is currently leading a 3-phase demonstration project in El Salvador that will screen 30 000 women by 2016 with an HPV test developed specifically for use in low-resource areas. Dr Maza has presented programme results and implementation strategies at international conferences and meetings held in Brazil, China, Guatemala, India, Panama, Peru and the USA. He believes in the need to advocate for more clinical and implementation research, in order to support more evidence-based policies in limited-resource settings.

Parallel session: "Implementation research"

Room: Gratte-Ciel (level 2) / 11:00 – 12:00

Thursday 9 June 2016

Friday 10 June 2016

Notes

Poster Sessions

Posters will be on display for the entire 3-day conference, in the poster area, on level –2.



The poster sessions will be held throughout the conference during the lunch breaks, and will be organized according to themes. To find the themes that interest you and the authors/posters you want to see, please refer to the floor plan on the following page and the schedule below.

You can find all the abstracts on the conference website, under the “programme” menu: www.iarc-conference2016.com/programme

Poster presenters will be standing by their posters, as follows:

WEDNESDAY, 12:15 – 14:00

EPIDEMIOLOGY	Global burden of cancer and cancer registries	Posters 1 to 60 (A)
MECHANISMS	Genetics and (epi)genomics	Posters 209 to 255 (G)
PREVENTION & MORTALITY REDUCTION	Challenges in primary prevention	Posters 319 to 334 (K)
	Implementation research	Posters 335 to 349 (L)
	Infection control to prevent cancer	Posters 350 to 359 (M)

THURSDAY, 12:55 – 14:30

EPIDEMIOLOGY	Nutrition, obesity and exercise	Posters 61 to 134 (B)
MECHANISMS	Systems perspectives of the exposome	Posters 256 to 269 (H)
	DNA damage, repair and mutagenesis	
	Bioinformatics	
	Mechanisms in carcinogen evaluation	Posters 270 to 280 (I)
PREVENTION & MORTALITY REDUCTION	Screening and early detection	Posters 360 to 402 (N)

FRIDAY, 12:55 – 14:00

EPIDEMIOLOGY	Environmental exposures	Posters 135 to 164 (C)
	Occupation	Posters 165 to 184 (D)
	Radiation	Posters 185 to 191 (E)
	Tobacco and alcohol in cancer	Posters 192 to 208 (F)
MECHANISMS	Metabolomics and biomarkers	Posters 281 to 318 (J)
PREVENTION & MORTALITY REDUCTION	Survival, survivorship and inequalities	Posters 403 to 437 (O)

INFORMATION FOR POSTER PRESENTERS

- All posters to be set up on Tuesday 7 June from 16:00 to 20:00 or Wednesday 8 June from 7:00 to 10:30.
- Take posters down by 17:30 on Friday (if you wish to take them back).

A team of volunteers will be there to help you find your slot and install your poster.
You just need to look for the IARC team T-shirt!

Poster Sessions

Floor plan of the Poster Area, on level –2



EPIDEMIOLOGY

- A** Global burden of cancer and cancer registries / 1–60
- B** Nutrition, obesity and exercise / 61–134
- C** Environmental exposures / 135–164
- D** Occupation / 165–184
- E** Radiation / 185–191
- F** Tobacco and alcohol in cancer / 192–208

MECHANISMS

- G** Genetics and (epi)genomics / 209–255
- H** Systems perspectives of the exposome / DNA damage, repair and mutagenesis / Bioinformatics / 256–269
- I** Mechanisms in carcinogen evaluation / 270–280
- J** Metabolomics and biomarkers / 281–318

PREVENTION & MORTALITY REDUCTION

- K** Challenges in primary prevention / 319–334
- L** Implementation research / 335–349
- M** Infection control to prevent cancer / 350–359
- N** Screening and early detection / 360–402
- O** Survival, survivorship and inequalities / 403–437

Satellite Meetings



SOIRÉE GRAND PUBLIC : AVANCER CONTRE LE CANCER

Date: Monday 6 June 2016, 18:30 – 21:30

Venue: IARC, 150 Cours Albert Thomas, 69008 Lyon, France

Attendance is free of charge, but seats are limited and pre-registration is mandatory.

In association with the conference celebrating its 50th anniversary (7–10 June 2016), IARC is organizing on its premises a public event in the evening on Monday 6 June, in collaboration with the Institut National du Cancer (INCa), the Centre de Recherche en Cancérologie de Lyon (CRCL), the Centre Léon-Bérard, the Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) and the Hospices Civils de Lyon (HCL). The presentations, in French, will focus on the progress in the fight against cancer over the past 50 years.

More information at:

www.canceropole-clara.com/manifestations/CIRC/



IMPLEMENTATION SCIENCE IN CANCER PREVENTION AND CONTROL

Date: Saturday 11 June 2016, 9:00 – 18:00

Venue: IARC, 150 Cours Albert Thomas, 69008 Lyon, France

Attendance is free of charge, but seats are limited and pre-registration is mandatory.

Implementation science is the study of methods to promote the integration of research findings and evidence into healthcare policy and practice. This newly emerging field intends to investigate and address major barriers (e.g. social, behavioural, economic, management) that prevent effective implementation, test new approaches to improve health programming, as well as determine a causal relationship between the intervention and its impact. This workshop, jointly organized by the Division of Cancer Control and Population Sciences (DCCPS) of the United States National Cancer Institute and the IARC Prevention and Implementation Group, is a free full-day training that will allow participants to learn how to define implementation science and understand its application in cancer prevention and early detection in various health care and public health settings.

More information at:

<http://iarc-conference2016.com/implementation-science>



SCIENTIFIC SYMPOSIUM CHERNOBYL: 30 YEARS AFTER

Date: Saturday 11 June 2016, 9:00 – 18:00

Venue: IARC, 150 Cours Albert Thomas, 69008 Lyon, France


Attendance is free of charge, but seats are limited and pre-registration is mandatory.

26 April 2016 marked the 30th anniversary of the Chernobyl accident, which led to the most serious exposure of a human population to ionizing radiation since the atomic bombings of Hiroshima and Nagasaki. On this occasion, a symposium will be held on Saturday 11 June 2016 at IARC. The aim of the Symposium will be to overview the current knowledge on the long-term health consequences of the accident that has been gained through numerous studies in the last three decades, to discuss future research directions that will help to improve our understanding of the long-term effects of ionizing radiation on human health and to consolidate our efforts to streamline future multidisciplinary studies.

More information at:

<http://iarc-conference2016.com/chernobyl-scientific-symposium>

Satellite Meetings



EPIGENETICS AND ENVIRONMENTAL ORIGINS OF CANCER

Date: Saturday 11 June 2016, 9:00 – 18:00

Venue: IARC, 150 Cours Albert Thomas, 69008 Lyon, France

Attendance is free of charge, but seats are limited and pre-registration is mandatory.

There is currently widespread recognition that epigenetics has moved from the periphery to the centre stage of cancer research. Recent studies contributed to the identification of epigenetic events deregulated by specific environmental and lifestyle stressors, and these findings continue to deepen our understanding of the mechanisms of carcinogenesis, particularly those linked to risk-factor exposures and ageing. In addition, important insights into epigenetic mechanisms and associated exposure risk factors have had a functional impact on the etiologies of specific human cancers. The goals of this meeting are to evaluate the recent scientific knowledge in the field of epigenetics and environmental origins of cancer, to determine future research needs in this area, and to assess the implications of such studies in cancer causation and prevention. We will also discuss how advances in epigenomics and the emergence of powerful technologies as well as state-of-the-art in vitro approaches may help in understanding mechanisms underlying epigenome deregulation by the environment and identifying epigenetic biomarkers. The meeting will bring together a group of leading scientists in the field in order to provide the best forum for discussion on recent advances in cancer epigenetics and environment, provide advice on ongoing activities and form a basis for new initiatives and collaborations.

More information at:

<http://iarc-conference2016.com/ege-meeting>



4th WORKSHOP ON EMERGING ISSUES IN ONCOGENIC VIRUS RESEARCH

Date: 15–19 June 2016

Venue: San Pietro in Bevagna, Manduria, Italy

Registration is mandatory as seats are limited.

The success of the first three Emerging Oncogenic Viruses workshops (held in 2010, 2012, and 2014) and the enthusiastic feedback from the participants (about 120 top scientists) have encouraged us to repeat the event in 2016 and to broaden the workshop's scope. The meeting will still focus on novel oncogenic viruses, but will also include new insights on well-established oncogenic viruses. We have slightly modified the name of the workshop to reflect this expanded focus. This meeting, intended for basic researchers (biologists and epidemiologists) as well as clinicians, is co-organized and sponsored by the International Agency for Research on Cancer (IARC) and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), with additional support from other international and Italian institutes. The objectives are to discuss and to critically evaluate the epidemiology, immunology, and biology of cancer-associated viruses.

More information at:

<http://www.iarc.fr/oncogenicviruses2016/>



6 – 9 November 2016
BT Convention Centre
Liverpool, UK

Join us at the
2016 NCRI Cancer Conference
The UK's largest cancer research meeting

Take advantage of
earlybird rates

Deadline:
30 June 2016

Late breaking
abstract submission
opens

1 August 2016

Topics include:

- Science journalism
- Radiobiology and prostate cancer
- Immunotherapy
- APOBECs and relevance to cancer
- Phase III trials
- Surgical oncology
- ... and many more

Confirmed speakers include:

- **Kat Arney**
*Freelance science writer and broadcaster
London, UK*
- **Rob Bristow**
University of Toronto, Canada
- **David Currow**
Flinders University, Australia

- **Lieping Chen**
Yale School of Medicine, USA
- **Iain Hagan**
*Cancer Research UK Manchester
Institute, UK*
- **Reuben Harris**
University of Minnesota, USA
- **Mark Krasnow**
Stanford University, USA
- **Charles Rudin**
*Memorial Sloan Kettering Cancer Center,
USA*
- **Alex Snyder**
*Memorial Sloan Kettering Cancer Center,
USA*
- **Jennifer Wargo**
MD Anderson Cancer Center, USA



Find out more by visiting conference.ncri.org.uk/2016



conference.ncri.org.uk

@NCRI #NCRI2016



Paris, France
31 Oct – 3 Nov 2016

Mobilising
Action
Inspiring
Change



Make 2016 count: play your part in the World Cancer Congress - the leading international forum for cancer implementation science

Engage with world class experts, harness the power of scientific evidence and translate knowledge into action.

Be ready for a highly interactive and innovative programme throughout the Congress week.

Track 1



Stemming the tide:

Innovations in prevention and screening

Track 2



Closing the gap:

Quality cancer treatment and diagnosis for all

Track 3



Improving patient and family experiences

Track 4



Strengthening cancer control:

Optimising outcomes of health systems

Track 5



Empowering civil societies:

Building capacity for change

Check out our latest programme, Big Debates, workshops, abstracts and more on www.worldcancercongress.org

Register now and benefit from our special 490€ offer only for IARC delegates: bit.ly/WCC_IARC50 Access code: 2016WCCIARC50



Follow us
#CancerCongress
#2016WCC
@UICC

Hosted by:



Practical Information



© UMR CNRS MAP - ENSAL

For its 50th anniversary scientific conference, IARC is delighted to welcome you to the Lyon Congress Centre, in the Cité Internationale district located in the Parc de la Tête d'Or.

REGISTRATION

Registration desks will be open as follows:

- Tuesday 7 June: 16:00 – 20:00
- Wednesday 8 June: 7:00 – 18:30
- Thursday 9 June: 8:00 – 19:00
- Friday 10 June: 8:00 – 17:00

BADGES

Upon check-in you will receive a personalized name badge. It must be clearly visible throughout the conference period and it will enable you to access all conference areas, coffee breaks as well as social events.

PUBLIC TRANSPORT PASS

Transportation day-passes, valid for the day on which first used, will be handed out with your badge. These will give you free access to local public transportation for the duration of the conference, from Wednesday to Friday.

POSTERS

Posters will be on display for the entire 3-day conference, on Level –2:

- All posters to be set up on Tuesday (16:00 – 20:00) or on Wednesday (7:00 – 10:30).
- Presenters must take their posters down by 17:30 on Friday (if they wish to take them back).

A team of volunteers will be there to help you find your slot and install your poster.

You just need to look for the IARC team T-shirt!

LUNCH BREAKS

Lunch will be served on Level –2, in the poster area:

- Wednesday 8 June: 12:15 – 14:00
- Thursday 9 June: 12:55 – 14:30
- Friday 10 June: 12:55 – 14:00

COFFEE BREAKS

Coffee breaks will be served every day on Level –2, including in the poster area:

- Every morning: 10:30 – 11:00
- Wednesday 8 June: 15:40 – 16:00
- Thursday 9 June: 15:30 – 16:00

CONFERENCE DINNER

The Conference Dinner will be served on Level –2. It will be preceded by a jazz concert in Amphithéâtre 3000. Please note that the dress code is informal. In general there will be free seating, although some tables have been allocated for invited guests, who will be notified.

INTERNET ACCESS

Free Wi-Fi will be available in all areas throughout the duration of the 3-day conference.

No password is required. The name of the network is **IARC50th**.

Practical Information

IARC ON TWITTER

If you wish to follow the conversation on Twitter and interact with other participants, our Twitter account is @IARCWHO and the hashtag for the conference is #IARC50.



WHAT'S ON YOUR MEMORY STICK?

Along with this programme and your badge, you have been given a memory stick. On it you will find:

- IARC brochure
- *International Agency for Research on Cancer: The First 50 Years, 1965–2015* (Saracci R and Wild CP)
- *World Cancer Report 2014* (Stewart BW and Wild CP, editors)
- IARC Monographs Volume 100

To see the abstracts presented throughout the conference, please visit the interactive programme on the conference website: www.iarc-conference2016.com/programme.

ACCESS

The Lyon Congress Centre may be reached on foot (approximately 5 km from the city centre) and by public or private transport.

BY BUS

Bus stop: "Cité Internationale"

- C1 bus from Lyon Part-Dieu train station
- C4 bus connects with metro lines A and D
- C5 bus from Bellecour square (Place Bellecour) and metro

BY BICYCLE

Lyon "vélo'v" service

Grand Lyon offers you an inexpensive popular bike-rental service that is simple and practical for short journeys. There is a station nearby (6036: "Cité Internationale / Musée d'art contemporain"), one of the 340 city bicycle stations.

BY TAXI

Taxi Lyon: +33 (0)4 72 10 86 86

Taxi Lyonnais: +33 (0)4 78 26 81 81

BY CAR

Large underground car parks are available in the Cité Internationale. Payment is required.

Car park P2 (853 spaces) is the nearest to the Congress Centre entrance.




QUESTIONS?

Should you have questions or require help, please ask at the registration desks or liaise with our wonderful team of volunteers (wearing IARC team T-shirts)!

Practical Information


Venue Map

The IARC conference is taking place on 5 levels of the Lyon Congress Centre:




LEVEL 2: GRATTE-CIEL

■ Gratte-Ciel rooms: parallel sessions on "Prevention & Mortality Reduction"




LEVEL 1: TÊTE D'OR

■ Salon Tête d'Or: Speakers' room
■ Tête d'Or rooms: parallel sessions on "Mechanisms"



LEVEL 0: CORDELIERS

■ Amphithéâtre 3000: plenary sessions, panel debates and parallel sessions on "Epidemiology"



LEVEL -1: BELLECOUR

■ Registration area
Cloakroom and luggage room
Press corner
Exhibition area

LEVEL -2: FORUMS

■ Opening reception, coffee and lunch breaks
■ Conference dinner
■ Poster area, coffee and lunch breaks

Partners

The International Agency for Research on Cancer acknowledges the contribution of:

GOLD SPONSORS



The Australian Government



SILVER SPONSORS



SUPPORTERS



International Agency for Research on Cancer



www.iarc-conference2016.com